Introduction
============

The past decade has seen unprecedented growth in the number of new, often high-cost, health technologies and consumer demand for access to them. It has also seen increased public awareness and scrutiny of decisions about which technologies to include in the basket of publicly insured services.[@b1-ceor-3-117]--[@b3-ceor-3-117] To improve the legitimacy of such decisions and optimize health outcomes through the effective use of increasingly strained health care resources, many payers, particularly those in Europe, have established centralized systems for determining the reimbursement status of new health technologies.[@b4-ceor-3-117],[@b5-ceor-3-117] In this invited review, we compare these systems across selected countries in Northern, Southern, Western, Eastern, and Central Europe, examining: Their mandate, authority, organizational structure, and policy optionsMechanisms for identifying, selecting, and evaluating technologiesClinical and economic evidence expectationsReview committee composition, procedures, and key factors considered during deliberationsUse of conditional reimbursement options for enabling access to promising new technologies around which considerable uncertainty related to clinical and/or economic value existsThe role of manufacturers in steps comprising the reimbursement review process.

Methods
=======

This review is based upon findings from a comprehensive search for publicly available information on centralized reimbursement systems in selected European countries. Peer-reviewed literature published in English over the past decade (ending in January 2011) was located using a structured search strategy that combined relevant controlled vocabulary terms, ie, MeSH and EMTREE (eg, "technology, medical," "reimbursement mechanisms," "decision-making," "technology assessment," "health policy") and free text terms (eg, "pharmaceuticals," "medical devices," "coverage," "funding," "centralized review," "health technology assessment," and "reimbursement," the full search strategy being available from the authors). Such terms were identified through an analysis of words used to index references familiar to the authors. The strategy was applied to several health-related electronic bibliographic databases, including PubMed, MEDLINE, EMBASE, HealthSTAR, CINAHL, EconLit, PASCAL, SCOPUS, International Pharmaceutical Abstracts, Web of Science, and the UK Centre for Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects, National Health Service Economic Evaluation Database, and Health Technology Assessment). For comprehensiveness, reference lists of retrieved papers and the most recent issues of health policy-related journals were hand-searched.

A search for gray (unpublished) literature (eg, working papers, conference abstracts, reports, presentations, government documents) was also performed using the Google^®^ search engine and terms from the main search strategy. In addition, the following dedicated gray literature databases were scanned: the New York Academy of Medicine's Gray Literature database, Knowledge Utilization database, Systematic Reviews for Management and Policy Making, and National Health Service Evidence in Health and Social Care. Separate searches for information on centralized reimbursement processes within health care systems of the top 30 European countries ranked according to gross domestic product per capita by the World Bank were also conducted. This number was considered sufficient to capture the full spectrum of such processes. For each country, the websites of relevant ministries (eg, health, social affairs, economics), translated into English with Google Translate^®^, were scanned for documents describing legislation and other policies and processes for making reimbursement decisions on new health technologies, including pharmaceuticals, medical devices, diagnostic tests, and procedures.

Documents retrieved from the various searches were reviewed independently by two of the authors. Published papers unrelated to the introduction of individual health technologies (eg, those on macrolevel priority setting) were excluded. Because the purpose of this review was to examine current actual processes, papers proposing specific decision-making tools or discussing one component of decision-making were also excluded. Information on process-related characteristics of the centralized reimbursement systems, including perceived strengths and weaknesses, was extracted using a standardized, pretested data abstraction form. To ensure it reflected the current policy environment, the following individuals were consulted: corresponding authors of published papers, contacts listed on organizations' websites, and European policy experts with whom the authors were already acquainted.

Extracted information was tabulated to facilitate the identification of patterns or trends across country-specific reimbursement processes, and subsequently analyzed qualitatively using content analysis and constant comparison techniques.

Results
=======

Of the 30 European countries initially identified for the review, information on centralized reimbursement processes could only be found for 23. Therefore, the review included the following 23 countries: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Norway, Poland, Portugal, Scotland, Slovakia, Spain, Sweden, Switzerland, the Netherlands, the United Kingdom, and Wales.

Mandate of centralized reimbursement systems
--------------------------------------------

The majority (18/23) of countries have established centralized reimbursement processes to support coverage decision-making for either pharmaceuticals or pharmaceuticals and devices needed for their delivery. In general, eligible pharmaceuticals comprise those requiring a prescription. Two-thirds of such processes review both inpatient and outpatient pharmaceuticals (12/18), while one-third (6/18) considers those administered in outpatient settings only ([Table 1](#t1-ceor-3-117){ref-type="table"}). The remaining five countries have invested in centralized reimbursement systems that span medical devices, procedures, and pharmaceuticals ([Table 1](#t1-ceor-3-117){ref-type="table"}). Despite differences in the scope of technologies included, such processes share a similar mandate to determine the reimbursement status of new technologies. In most of the countries, this amounts to a decision on whether to add the technology to a "positive list" (ie, list of insured services). However, a small proportion of the countries also maintain a "negative list" (ie, a list of nonreimbursable services), broadening the mandate of their centralized reimbursement systems to include decisions resulting in active exclusion of some technologies from the benefit plan ([Table 1](#t1-ceor-3-117){ref-type="table"}). In legislation governing most systems (13/23), decisions are authoritative (ie, must be implemented), rather than advisory (ie, recommendations). Given that the price of a technology can significantly influence assessments of value for money and affordability, many of the countries have also incorporated pricing into the mandates of such systems (discussed in detail later). Finally, all consider at least three funding decision options, ie, provide, do not provide, and provide with restrictions or conditions (ie, restrict use to specific providers or patients meeting certain criteria, [Table 1](#t1-ceor-3-117){ref-type="table"}). In addition, approximately one-third have introduced a fourth option, ie, provide while additional evidence is collected. The latter comprises a provisional funding arrangement in which the technology is reimbursed in the interim while information needed to reduce uncertainties in existing evidence is collected to support a definitive decision.

Assessment of health technologies in centralized reimbursement systems
----------------------------------------------------------------------

Approaches to the identification of technologies for review by centralized reimbursement systems vary across countries ([Table 2](#t2-ceor-3-117){ref-type="table"}). Broadly, there are three strategies: technologies may be submitted by manufacturers seeking coverage for newly licensed pharmaceuticals (13/23); they may be referred by potential payers (eg, government, sickness funds) or users (eg, hospitals, providers, patients), as well as manufacturers (8/23); or they may be identified by payers or users only (2/23). Systems limited to consideration of reimbursement applications from manufacturers alone typically review submissions in order of receipt, unless a technology is eligible for "fast tracking," which moves it to the front of the queue. In countries with such mechanisms (eg, the Netherlands), eligibility criteria include technologies (mainly pharmaceuticals) used to treat rare or life-threatening conditions for which no alternatives beyond best supportive care exist. Some countries (eg, Scotland and Norway) have more closely linked centralized regulatory and reimbursement processes in order to reduce overall inefficiencies in technology policy. Specifically, pharmaceuticals are automatically sent to the centralized reimbursement system for review upon market approval. In systems that accept referrals from multiple stakeholders, technology selection and/or prioritization criteria have been established. For example, Germany's Federal Joint Committee, which determines which technologies to review, takes into account clinical relevance, cost implications, and potential "risks" related to the technology and its introduction into the health care system.[@b6-ceor-3-117] In the UK, the topic selection panel of the National Institute of Health and Clinical Excellence, whose members include health care providers and patient representatives, formulate recommendations following consideration of: the burden of disease for which the technology targets; anticipated clinical impact (ie, whether the technology represents a significant medical advance that could yield substantial health benefits); potential impact on National Health Service costs and resources; alignment of the technology with broader government priority areas; concerns over appropriateness of use in practice; and potential for national guidance to add value.[@b7-ceor-3-117] Recommendations are forwarded to the Department of Health, which makes the final decision.

Across centralized reimbursement systems, technology identification and selection is followed by some form of health technology assessment ([Table 2](#t2-ceor-3-117){ref-type="table"}). This involves collection and synthesis of evidence (clinical and, in most cases, economic), the findings of which are presented in an assessment report, and critical appraisal of the relevance, quality, and generalizability of that evidence. The results of the latter are summarized in an evaluation report. Responsibility for the preparation of these reports varies. In systems where a manufacturer's submission initiates the reimbursement review process, the assessment report is part of the submission ([Table 2](#t2-ceor-3-117){ref-type="table"}). Therefore, its preparation rests with the manufacturer. Most systems have developed a standard template/structure for the report and submission guidelines to which manufacturers must adhere. These guidelines largely include content/information requirements and internationally accepted methods for synthesizing and analyzing evidence. In two of the countries, responsibility for the assessment depends upon the type of review ("appraisal"). Both France and the UK have created "single technology appraisal" and "multiple technology appraisal" processes. "Single technology appraisals" compare the candidate technology with a limited number of alternatives for a specific, well-defined indication (eg, disease stage). Their scope most closely resembles processes based upon manufacturers' submissions. "Multiple technology appraisals" consider either several indications for a candidate technology or several technologies (along with the candidate technology) for a condition at one or more points in its course, taking a disease management approach. The assessment report for a single technology appraisal is prepared by the manufacturer. For a multiple technology appraisal, the report is drafted either internally with support from external content and methodological experts (France) or by an independent academic group (the UK). Finally, in some countries, technical staff of a dedicated health technology assessment body or the centralized reimbursement system itself undertake the assessment report, regardless of the scope (eg, Germany).

With one exception (the UK), responsibility for preparing the evaluation report that accompanies each assessment also lies with technical staff and, if necessary, external experts. The National Institute of Health and Clinical Excellence commissions independent academic groups to evaluate assessments submitted by manufacturers as part of its single technology appraisal process.

Clinical and economic evidence expectations of centralized reimbursement systems
--------------------------------------------------------------------------------

Centralized reimbursement systems have issued their own guidelines or endorsed internationally recognized published ones specifying clinical and economic evidence requirements for assessment reports ([Tables 3](#t3-ceor-3-117){ref-type="table"} and [4](#t4-ceor-3-117){ref-type="table"}). These guidelines state topics to be addressed and the types of information accepted for addressing them. In most cases (16/23), specified clinically-related topics are similar and include: burden of illness and/or characteristics of the target patient population; therapeutic claim of the candidate technology; safety; efficacy; and effectiveness (preferably comparative effectiveness) across relevant patient subgroups ([Table 3](#t3-ceor-3-117){ref-type="table"}). Additionally, several require information on current management or the place of the candidate technology within existing treatment pathways (eg, France and the UK), and its proposed frequency and duration of use (eg, Austria). Across systems and where reported, there is a shared preference for information on health outcomes that represent final clinical endpoints related to mortality, morbidity, and quality of life. Less frequently, information on adverse events/complications is also required. This may be explained by the fact that a prerequisite for reimbursement review is typically regulatory approval. Therefore, systems may view reconsideration of adverse events, which relate to the safety of a technology, unnecessary. In systems proposing or stipulating the use of quality-adjusted life-years (7/23), change in health-related quality of life is to be measured in patients and then valued in the public or general population (eg, the UK). Surrogate outcomes are discouraged or not accepted unless well validated (eg, Germany). Lastly, some systems elicit the views of patients and or carers in identifying topic specific outcomes and their relative importance (eg, Germany).

In general, centralized reimbursement systems state a preference for head-to-head randomized controlled trials comparing the candidate technology with standard care, no active treatment/best supportive care, or placebo (if no alternatives exist, [Table 3](#t3-ceor-3-117){ref-type="table"}). However, increased interest in evidence of "comparative effectiveness" over "comparative efficacy" among most reimbursement systems has led to requests for inclusion of head-to-head randomized controlled trials conducted in "naturalistic settings" (ie, pragmatic trials, in the UK) and other direct comparative studies (observational and experimental in design), the collective findings of which may offer a more accurate prediction of the behavior of the technology in general clinical practice (eg, France, Germany, and Sweden). Also, there appears to be emerging recognition of the need for flexibility in evidence expectations under certain circumstances. Recently, Germany's Institute for Quality and Efficiency in Health Care, which conducts health technology assessments and makes reimbursement recommendations on selected health technologies to the Federal Joint Committee, issued methodological guidelines suggesting that when no active alternative treatment exists, well designed case series would be deemed adequate.[@b8-ceor-3-117]

While across systems, the preferred source of such clinical evidence is published, peer-reviewed studies, many encourage, and in several cases require if available, inclusion of unpublished or ongoing studies (eg, Austria, Belgium, Norway, Poland, Slovakia, Sweden, the Netherlands, and the UK), commercial in-confidence data (eg, Austria, France, Sweden, and the UK) and/or current national and international clinical practice guidelines (eg, France) in assessment reports. In recent years, some systems have incorporated submissions from patient and/or carer organizations into their processes (eg, Scotland, Sweden, and the UK). Such submissions are increasingly viewed as an important source of information regarding the relative value of outcome measures employed in clinical studies and the meaningfulness or significance of findings to patients and carers. Finally, while systems tend not to explicitly exclude sources of information, Belgium's Drug Reimbursement Committee states that abstracts are not accepted.[@b9-ceor-3-117]

Most centralized reimbursement systems (20/23) have made mandatory the inclusion of a formal economic evaluation/analysis for either some (ie, those for which alternative(s) exist(s), eg, Germany, or those offering "added therapeutic value," eg, Austria and Belgium, or all candidate technologies to inform deliberations around "value for money" and/or "efficiency." In the latter case, the type of evaluation is rarely stipulated, because options available depend, in part, on the magnitude of the incremental benefit of the technology over its comparators. However, a rationale must be presented, and methods adopted must comply with economic guidelines developed or endorsed by the centralized reimbursement system ([Table 4](#t4-ceor-3-117){ref-type="table"}). For technologies that appear to offer "added therapeutic value" (ie, are more effective), some systems indicate a preference for certain types of evaluations, such as cost-utility analysis by Ireland's Health Service Executive.[@b10-ceor-3-117] Others state explicitly which types will not be accepted, such as cost-benefit analysis by Belgium's Drug Reimbursement Committee.[@b11-ceor-3-117] In addition to a formal economic evaluation, the Institute for Quality and Efficiency in Health Care in Germany requires an efficiency frontier analysis, which assesses the relative value of different technologies within a given therapeutic area.[@b12-ceor-3-117] Regarding the perspective to be taken for the economic evaluation, the proportion of systems adopting a "payer," "societal," or both "payer" and "societal" perspective is similar. Among systems considering a payer's perspective only, costs to be captured are often restricted to those directly related to care associated with the use of the candidate technology throughout the course of a disease or condition (ie, direct costs to the health care system). One exception is the National Institute of Health and Clinical Excellence, which specifies inclusion of direct and indirect costs to the National Health Service and Personal Social Services.[@b13-ceor-3-117] In systems requiring a societal perspective, costs specified comprise direct costs to not only the health care system, but also services beyond health care and indirect (lost productivity) costs. However, they must be reported separately (eg, Finland, Portugal, and the Netherlands). In Sweden, The Dental and Pharmaceutical Benefits Board has taken a wider view on indirect costs, requesting that time lost by patients and carers be considered, along with lost productivity.[@b14-ceor-3-117],[@b15-ceor-3-117] Thus, its methods broadly resemble those of "holistic" economic analysis, a technique initially developed for economic evaluations of public programs, the costs and benefits of which are often complex. Nevertheless, considerable debate over the valuation of items such as "time lost" within academic and policy communities remains. This may be why other systems employing a societal perspective have assumed a narrower position on eligible indirect costs. With respect to the choice of comparator for the economic evaluation, almost all systems specify use of one of the following: "standard care," "the most commonly used alternative," or "alternative most likely to be replaced." France also requires separate analyses with two additional comparators, ie, the most recently reimbursed alternative and the least expensive alternative.[@b16-ceor-3-117] In Belgium, if the candidate technology represents an "addon" treatment, the comparator must constitute current treatment without the candidate technology.[@b17-ceor-3-117] Further, the use of "offlabel" treatments as the comparator is not permitted.[@b11-ceor-3-117] All systems rely upon sensitivity analyses to assess the stability of estimates generated through the economic evaluation, but few stipulate the type. Among those that do, probabilistic sensitivity analysis is the most commonly prescribed (eg, Belgium, Germany, Scotland, Slovakia, the UK, and Wales).

In recent years, affordability has become an increasingly important consideration for centralized reimbursement systems, with almost all of those included in this review (where information could be found) requiring a budget impact analysis ([Table 4](#t4-ceor-3-117){ref-type="table"}). However, some waive this analysis in certain circumstances, eg, when no alternative treatment exists (Belgium).[@b17-ceor-3-117] Although information describing the specific costs to be included appears scarce, based on that available, they mirror those for the economic evaluation of the same technology. Specifically, if the economic evaluation is limited to direct costs, so must the budget impact analysis, eg, Hungary and Ireland.

Reimbursement decisions: review committee composition, procedures, and key factors
----------------------------------------------------------------------------------

In most of the centralized reimbursement systems, the assessment and evaluation reports are sent to and scrutinized by a review committee (sometimes referred to as an appraisal committee). While the composition of this committee varies across systems, it is usually multidisciplinary, with members representing payers, administrators, health care providers, and academia (eg, health economists, [Table 5](#t5-ceor-3-117){ref-type="table"}). Approximately one-third have also appointed patient representatives to their respective committees (eg, Sweden, Switzerland, and the UK), although not always as voting members (Germany),[@b18-ceor-3-117],[@b19-ceor-3-117] and one-fifth include manufacturers (Belgium, Switzerland, the UK, and Wales). In most systems, the authority of the review committee is advisory (ie, makes recommendations). Aside from lists of factors/criteria considered ([Table 6](#t6-ceor-3-117){ref-type="table"}), publicly available procedural information on committee deliberations is often limited to conditions under which presentations/testimonials from external experts (including patients) are sought or accepted and whether an incremental cost-effectiveness ratio threshold is employed. Among the exceptions is France. There, review committees (the Commission d'Evaluation des Medicaments (CEM), followed by the Transparency Commission) adhere to a two stage process. First, the CEM assigns a "medical benefit" or "SMR" level/score to the candidate technology (a new pharmaceutical). The score is based on a five-point scale, with "I" representing "major medical benefit" and "V" representing "insufficient to justify reimbursement."[@b16-ceor-3-117],[@b20-ceor-3-117]--[@b23-ceor-3-117] Upon approval of the score by the Minister, the CEM then compares the technology with already reimbursed alternatives in order to formulate an opinion on the "improvement in medical benefit" or "ASMR" level. Six possible levels exist, ranging from I (major innovation) to VI (negative opinion regarding inclusion on the benefit list). Therefore, "innovativeness" is viewed as the size of the incremental clinical benefit achieved by the candidate technology. The opinion of the CEM is forwarded to the Transparency Commission, who makes a formal recommendation on the ASMR classification. This classification is, in turn, used to negotiate price and reimbursement rate. In Germany, the "innovativeness" of a technology is also based on whether it offers "added therapeutic value." Moreover, it plays an important role in determining the content of subsequent committee deliberations, because "cost-benefit" analyses are only taken into account when a technology has been deemed innovative.[@b18-ceor-3-117]--[@b24-ceor-3-117] The review committee of the Italian Medicines Agency, ie, the Technical Scientific Committee, explicitly weighs both the availability of existing treatments and the extent of clinical benefit in its assessment of a new pharmaceutical's innovativeness. The two attributes are scored separately and then combined to determine whether it represents an "important," "moderate," or "modest" innovation.[@b25-ceor-3-117] This rating, along with the category of clinical value to which the pharmaceutical has been assigned, is sent to a second review committee, ie, the Pricing and Reimbursement Committee, which negotiates price and reimbursement status with the manufacturer.[@b26-ceor-3-117],[@b27-ceor-3-117]

Regardless of the reimbursement system, one of the main goals of the review committee is to determine the "therapeutic value" of a candidate technology. Broadly, its assessment combines consideration of clinical benefit with that of clinical need, taking into account key factors related to each dimension. For clinical need, they comprise, at a minimum, burden of illness (prevalence of severity) of the target condition and availability of alternatives. For clinical benefit, they include at least safety (risk--benefit ratio) and efficacy/effectiveness, on the basis of which an overall estimate of the ratio of the benefits to harms of a candidate technology is estimated ([Table 6](#t6-ceor-3-117){ref-type="table"}). While a further goal shared by most review committees is to formulate an opinion on whether the candidate technology represents "value for money" or an efficient use of resources, their approach to accomplishing this differs. Approximately one-third are guided by, but not compelled to adhere to, a predefined incremental cost-effectiveness threshold or threshold range.[@b28-ceor-3-117],[@b29-ceor-3-117] Typically, if the incremental cost-effectiveness for a candidate technology lies below the threshold, it is deemed cost-effective or good value for money. If it lies above the threshold, additional factors are taken into account when judging acceptability (eg, uncertainties in estimates of outcomes, the severity of condition, and wider societal benefits).[@b30-ceor-3-117],[@b31-ceor-3-117] Across systems whose committees do not refer to an incremental cost-effectiveness threshold, approaches to operationalizing "value or money" appear vague, with information largely limited to statements such as "reasonableness of cost relative to therapeutic value" ([Table 6](#t6-ceor-3-117){ref-type="table"}).[@b32-ceor-3-117] Similarly, although all but one of the systems (Sweden[@b21-ceor-3-117]) list "affordability" or "impact of the candidate technology on health system resources" among factors/criteria considered by their respective review committees, no information describing processes for deciding whether or not a technology is affordable could be found.

Equity or ethical implications comprise decision-making factors/criteria (explicitly or implicitly) in one-third of systems. For example, Sweden's Dental and Pharmaceutical Benefits Board stipulates two principles that decisions must reflect, ie, the "need and solidarity principle" (patients in the greatest need or "worse off " must be given priority) and the "human value principle" (sociodemographic characteristics of patient populations cannot influence decisions).[@b21-ceor-3-117],[@b33-ceor-3-117] Along with "solidarity," the Norwegian Medicines Agency explicitly takes into account "equity," as do review committees in Hungary and Poland.[@b26-ceor-3-117],[@b34-ceor-3-117]--[@b36-ceor-3-117] However, the way in which this is accomplished during deliberations is not clear. Committees using an incremental cost-effectiveness threshold to guide decisions implicitly incorporate equity by virtue of the assumptions underpinning the incremental cost-effectiveness calculation (ie, each quality-adjusted life-year \[QALY\] carries the same weight, regardless of the characteristics of the patients receiving it (eg, age, gender, social status, income). Consideration of additional, often competing ethical principles by these committees is operationalized through "exception" conditions under which the normal "efficiency" expectations do not need to be met (eg, "last chance" therapies, orphan technologies, life-extending, end-of-life treatments).[@b37-ceor-3-117] Under such conditions, not all QALYs are deemed equal. Rather, a form of "solidarity" premium is applied, where, for example, QALYs gained in the later stages of disease are given greater weight. While there is little disagreement over the importance of instituting "exception" conditions as a means of ensuring that reimbursement decisions embody the broader values of the population, considerable debate around definitions/qualifiers (eg, what constitutes "last chance"? or by what period of time must a technology lengthen survival in order to be regarded as "life-extending"?) remains. Finally, the following factors are simply listed as criteria/factors by a small proportion of committees: alignment with government priorities; feasibility; and/or risk of off-label use of the technology ([Table 6](#t6-ceor-3-117){ref-type="table"}).

In general, systems aim to complete single technology reviews within 180 days of submission/identification of candidate technology, the time period prescribed by the European Union Transparency Directive. Based on tracking data, the actual time required appears to depend primarily on whether the assessment report accompanies a reimbursement application (eg, Belgium) or is undertaken (internally or externally) by the system once a technology is identified for review (eg, the UK, [Table 5](#t5-ceor-3-117){ref-type="table"}). In the latter case, review times can be 90 days or less (eg, Denmark and France).[@b20-ceor-3-117],[@b38-ceor-3-117]

The majority of systems have established mechanisms for appealing recommendations or decisions. Briefly, there are two main types of disputes, ie, those related to process and those amounting to disagreements over the interpretation of the evidence. In approximately one-third of systems, acceptable grounds for appeals are those of the first type only ("failed to act in accordance with processes"[@b39-ceor-3-117]). For the most part, appeals are heard by an expert panel appointed by the respective health care organization or "payer" (eg, Ministry of Health, [Table 5](#t5-ceor-3-117){ref-type="table"}). Alternatively, they must be filed in an administrative court (eg, Germany and Sweden).

Conditional reimbursement enabling access to new technologies
-------------------------------------------------------------

Increasingly, reimbursement systems are expressing interest in and/or implementing reimbursement policy options that extend beyond the traditional "yes," "no," or "yes with restrictions" options. Such policy options take the form of provisional reimbursement arrangements, in which funding for a technology is provided in the interim while evidence needed to make a definitive decision is collected.[@b40-ceor-3-117] Collectively referred to as "Access with Evidence Development" (AED) schemes, they have emerged in response to calls for mechanisms that balance access to new technologies with the need to ensure their safe, effective, and efficient introduction and use in the health care system. In recent years, these calls have heightened, as tension between payers and manufacturers, patients, and providers has intensified. Many new high-cost technologies are supported by limited, albeit promising, evidence. Therefore, reimbursement decisions are made under conditions of considerable uncertainty, with significant risks and consequences of "getting it wrong" (wasted scarce resources and poor health outcomes). AED schemes attempt to reduce such risks through "managed entry" of new technologies into everyday clinical practice. There are three main types, ie, coverage linked to an outcomes guarantee, coverage as part of a study, and automatic reassessment ([Table 7](#t7-ceor-3-117){ref-type="table"}). Often referred to as "risk-sharing" schemes, "patient access schemes," and "payment by results," the first type consists of contractual arrangements between payers and manufacturers, where payment is tied to the achievement of an outcome, be it financial or health-related.[@b41-ceor-3-117],[@b42-ceor-3-117] Such schemes have been employed in approximately one-third of the systems in this review ([Table 7](#t7-ceor-3-117){ref-type="table"}). They include financially-based price-volume agreements, where manufacturers must "pay back" the cost of sales exceeding those forecasted (eg, Belgium, France, Germany, Hungary, Portugal),[@b41-ceor-3-117],[@b43-ceor-3-117],[@b44-ceor-3-117] and expenditure caps, in which manufacturers cover the cost of "treatment" in patients for whom costs over a fixed time period exceed a prespecified amount (eg, Italy, the UK).[@b41-ceor-3-117],[@b45-ceor-3-117] Health-related risk sharing arrangements, also called "no cure no pay" schemes, have been implemented by a smaller proportion of systems (Belgium, Denmark, Italy, the UK).[@b41-ceor-3-117],[@b45-ceor-3-117]--[@b47-ceor-3-117] Under such schemes, continued reimbursement of a technology (usually a pharmaceutical for a rare disorder or cancer) requires evidence of a predefined treatment effect. The second type, "coverage as part of a study," involves provision of interim funding by payers in order to conduct studies designed to collect specific information needed to fill key evidence gaps. Typically, such evidence gaps relate to the effectiveness and/or cost implications of the technology in "real world" settings. Funding may be partial (costs of the technology and/or health care associated with its use) or full (all health care and research costs). This type of scheme constitutes a policy option in approximately one quarter of the reimbursement systems, the majority of which have mandates that span pharmaceutical and nonpharmaceutical technologies (eg, France, Germany, the UK, [Table 7](#t7-ceor-3-117){ref-type="table"}). Eligible technologies vary across systems, but often include those defined as "innovative" (eg, granted an "innovation pass" in the UK) and those anticipated to significantly impact health care organization budgets (eg, the Netherlands).[@b25-ceor-3-117],[@b48-ceor-3-117] The third type of AED scheme, "automatic reassessment," comprises a programmed review of a reimbursement decision following a fixed period on the "benefit list" or when additional evidence is available.[@b49-ceor-3-117]--[@b51-ceor-3-117] It has become a part of the policy framework in half of the reimbursement systems included in this review, with most requiring reassessments of all technologies within their decision-making scope ([Table 7](#t7-ceor-3-117){ref-type="table"}). Despite the appeal of AED schemes, evidence of their effectiveness is both limited and mixed. Recent reviews have highlighted the challenges involved in both their design and implementation.[@b52-ceor-3-117],[@b53-ceor-3-117] Such challenges primarily stem from the need to reach consensus among stakeholders on the terms of the scheme. Often, considerable time and resources have been required to resolve disagreements over elements such as the value proposition, outcomes to be measured and for what period, how the scheme should be funded, and to whom its oversight should be handed. Further, negotiations have, in some cases, resulted in complex arrangements that failed to generate the evidence needed to support a policy decision and/or created a significant administrative burden on payers and providers involved in its implementation. In an effort to address these issues, guidelines for conducting AED schemes, derived from international experiences to date, were recently published.[@b53-ceor-3-117],[@b54-ceor-3-117] Moreover, some systems have proposed alternative approaches to dealing with decision uncertainties. For example, earlier this year, National Institute of Health and Clinical Excellence announced a new form of value-based reimbursement termed "flexible pricing."[@b45-ceor-3-117]--[@b48-ceor-3-117] Under this approach, manufacturers adjust the price of a technology (pharmaceutical) in response to additional evidence of actual benefit to patients as it emerges. The National Institute of Health and Clinical Excellence subsequently assess this evidence, along with the proposed price, and determines whether the technology represents "value for money." If a negative opinion is reached, the National Institute of Health and Clinical Excellence may veto the proposed price. Given the potential benefits of such an approach (eg, reduced administrative burden and system resource requirements) it has already sparked interest among the National Institute of Health and Clinical Excellence's counterparts across Europe.

Role of manufacturers in steps comprising the reimbursement review process
--------------------------------------------------------------------------

Few reimbursement systems have established roles for manufacturers beyond referral of a technology for review and the opportunity to comment on draft reports and/or preliminary recommendations ([Table 8](#t8-ceor-3-117){ref-type="table"}). Where "multiple technology appraisal" processes exist and assessment reports are commissioned or undertaken by the reimbursement system, manufacturers may participate in defining the scope or protocol of the assessment (France, Germany, the UK) or submit information to the group preparing such reports (Germany, Ireland, Spain, the UK). Among systems that prepare the evaluation report only, about half invite manufacturers to contribute information (Scotland, Italy, Sweden, the UK, Wales). Involvement of manufacturers otherwise appears limited to single examples, eg, able to participate in consultations during the assessment (France) or attend review committee meetings (Wales).

Conclusion
==========

Centralized reimbursement systems have become an important policy tool in many European countries. Their introduction has, inarguably, brought greater consistency to processes and an improved sense of legitimacy to decisions. Nevertheless, there remains a lack of transparency around critical elements, such as how multiple factors or criteria are weighed during committee deliberations. Further, empirical studies evaluating the extent to which centralized reimbursement systems with advisory as opposed to decision-making authority are able to reduce inequities in access to new technologies within jurisdictions appear sparse.

Given the rapid pace with which new technologies that appear promising are now entering the market and the need to work alongside broader government industrial policies for encouraging innovation in an economic climate that demands prudent use of strained health care resources, the adoption of AED schemes by reimbursement systems seems inevitable. However, until more information on the outcomes of initiatives such as flexible pricing in the UK becomes available, their implementation should be approached with caution.
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Centralized reimbursement system and mandate

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                                                                    **Technology scope**                                                                                                                                   **Decision problem**                                                                                                                                **Decision "scope"**                                                         **Available decision options**                                                                                                                                                                                
  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ----------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board/Austrian Medicines Evaluation Commission (recommendations)[@b21-ceor-3-117],[@b56-ceor-3-117]--[@b58-ceor-3-117]   Pharmaceuticals -- Outpatient[@b55-ceor-3-117]                                                                                                         Provide as publicly insured service (reimbursable)[@b55-ceor-3-117]Do not provide as publicly insured service (nonreimbursable)[@b55-ceor-3-117]    Yes[@b56-ceor-3-117],[@b59-ceor-3-117]                                       Yes[@b21-ceor-3-117],[@b56-ceor-3-117],[@b59-ceor-3-117]                     Yes[@b56-ceor-3-117]                       Yes[@b56-ceor-3-117]                       Yes[@b56-ceor-3-117]                       Not specified

  Belgium           Minister of Social Affairs (decisions)Commission on reimbursement of medicines/Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]--[@b63-ceor-3-117]                                                  Pharmaceuticals -- Outpatient-- Inpatient[@b21-ceor-3-117],[@b64-ceor-3-117]                                                                           Provide as publicly insured service (reimbursable)[@b21-ceor-3-117]                                                                                 Yes[@b21-ceor-3-117]                                                         Yes[@b21-ceor-3-117]                                                         Yes[@b21-ceor-3-117]                       Yes[@b21-ceor-3-117]                       Yes[@b21-ceor-3-117]                       Yes[@b21-ceor-3-117]

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117]--[@b67-ceor-3-117]                                                                                                                                                    Pharmaceuticals -- Outpatient[@b65-ceor-3-117]                                                                                                         Provide as publicly insured service (reimbursable)[@b65-ceor-3-117]                                                                                 Yes[@b67-ceor-3-117]                                                         Yes[@b67-ceor-3-117]                                                         Yes[@b65-ceor-3-117]                       Yes[@b65-ceor-3-117]                       Yes[@b65-ceor-3-117]                       Not specified

  Denmark           Danish Medicines Agency (decisions).[@b68-ceor-3-117]--[@b70-ceor-3-117] Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b70-ceor-3-117]                                                                               Pharmaceuticals -- Outpatient[@b71-ceor-3-117]                                                                                                         Provide as publicly insured service[@b38-ceor-3-117],[@b46-ceor-3-117],[@b69-ceor-3-117],[@b71-ceor-3-117]                                          Yes[@b68-ceor-3-117]                                                         No[@b68-ceor-3-117]                                                          Yes[@b38-ceor-3-117],[@b69-ceor-3-117]     Yes[@b38-ceor-3-117],[@b69-ceor-3-117]     Yes[@b38-ceor-3-117],[@b69-ceor-3-117]     Not specified

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                                                                 Pharmaceuticals -- Outpatient[@b72-ceor-3-117]                                                                                                         Provide as publicly insured service (reimbursable)[@b72-ceor-3-117]                                                                                 Yes[@b72-ceor-3-117]                                                         Yes[@b72-ceor-3-117]                                                         Yes[@b72-ceor-3-117]                       Yes[@b72-ceor-3-117]                       Yes[@b72-ceor-3-117]                       No[@b67-ceor-3-117]

  Finland           Pharmaceuticals Pricing Board (decisions)[@b64-ceor-3-117],[@b73-ceor-3-117],[@b74-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]                                                         Pharmaceuticals -- Outpatient[@b76-ceor-3-117]                                                                                                         Provide as publicly insured service (reimbursable)[@b76-ceor-3-117]Do not provide as publicly funded service (nonreimbursable)[@b76-ceor-3-117]     Yes[@b76-ceor-3-117]                                                         Yes[@b76-ceor-3-117]                                                         Yes[@b77-ceor-3-117]                       Yes[@b73-ceor-3-117]                       Yes[@b73-ceor-3-117]                       No[@b74-ceor-3-117]

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                                                                       Pharmaceuticals -- Outpatient-- Inpatient[@b79-ceor-3-117]Devices[@b79-ceor-3-117]Procedures[@b79-ceor-3-117]                                          Provide as publicly insured service (reimbursable)[@b80-ceor-3-117]                                                                                 Yes[@b16-ceor-3-117],[@b20-ceor-3-117],[@b22-ceor-3-117],[@b78-ceor-3-117]   Yes[@b16-ceor-3-117],[@b20-ceor-3-117],[@b22-ceor-3-117],[@b78-ceor-3-117]   Yes[@b20-ceor-3-117]                       Yes[@b20-ceor-3-117]                       Yes[@b20-ceor-3-117]                       Yes[@b16-ceor-3-117],[@b20-ceor-3-117]

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117]                                                                                          Pharmaceuticals -- Outpatient-- Inpatient[@b81-ceor-3-117],[@b82-ceor-3-117]Devices[@b18-ceor-3-117]Procedures[@b83-ceor-3-117]                        Provide as publicly insured service (reimbursable)[@b55-ceor-3-117]Do not provide as publicly funded service (nonreimbursable)[@b55-ceor-3-117]\    Yes[@b19-ceor-3-117]                                                         Yes[@b82-ceor-3-117],[@b84-ceor-3-117]                                       Yes[@b19-ceor-3-117]                       Yes[@b19-ceor-3-117]                       Yes[@b19-ceor-3-117]                       Yes[@b19-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                               Note: Must not exclude technologies for which there is no alternative[@b18-ceor-3-117],[@b81-ceor-3-117]                                                                                                                                                                                                                                                                                                                                       

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117],[@b86-ceor-3-117]                                                                                                             Pharmaceuticals -- Outpatient[@b85-ceor-3-117]                                                                                                         Classify pharmaceutical into therapeutic category[@b85-ceor-3-117]                                                                                  Yes[@b85-ceor-3-117]                                                         Yes[@b87-ceor-3-117]                                                         N/A                                        N/A                                        N/A                                        N/A

  Hungary           Ministers of Health and Finance (decisions)National Health Insurance Fund Administration Health Technology Assessment Committee (recommendations)[@b88-ceor-3-117],[@b89-ceor-3-117]                                                Pharmaceuticals -- Outpatient-- Inpatient[@b90-ceor-3-117]                                                                                             Provide as publicly insured service[@b88-ceor-3-117]Do not provide as publicly funded service (nonreimbursable)[@b26-ceor-3-117]                    Yes[@b88-ceor-3-117]                                                         Not specified                                                                Yes[@b90-ceor-3-117]                       Yes[@b90-ceor-3-117]                       Yes[@b90-ceor-3-117]                       Not specified

  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                                                                                             Pharmaceuticals -- Outpatient-- InpatientDevicesProcedures[@b91-ceor-3-117],[@b92-ceor-3-117]                                                          Provide as publicly insured service (reimbursable)[@b92-ceor-3-117]                                                                                 Yes[@b91-ceor-3-117]                                                         No[@b91-ceor-3-117]                                                          Yes[@b91-ceor-3-117]                       Yes[@b91-ceor-3-117]                       Yes[@b91-ceor-3-117]                       No[@b93-ceor-3-117]

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]                                                 Pharmaceuticals -- Outpatient-- Inpatient[@b21-ceor-3-117]                                                                                             Provide as publicly insured service (reimbursable)[@b21-ceor-3-117]                                                                                 Yes[@b96-ceor-3-117],[@b97-ceor-3-117]                                       Yes[@b96-ceor-3-117],[@b97-ceor-3-117]                                       Yes[@b96-ceor-3-117]                       Yes[@b96-ceor-3-117]                       Yes[@b96-ceor-3-117]                       Yes[@b96-ceor-3-117]

  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]                                                                                                           Pharmaceuticals -- Outpatient-- Inpatient[@b34-ceor-3-117]                                                                                             Provide as publicly insured service (reimbursable)[@b98-ceor-3-117]                                                                                 Yes[@b98-ceor-3-117]                                                         Yes[@b98-ceor-3-117]                                                         Yes[@b98-ceor-3-117]                       Yes[@b98-ceor-3-117]                       Yes[@b98-ceor-3-117]                       Not specified

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117]                                                                                                                                                                                     Pharmaceuticals -- Outpatient-- Inpatient[@b100-ceor-3-117]                                                                                            Provide as publicly insured service (reimbursable)[@b100-ceor-3-117]                                                                                Yes[@b100-ceor-3-117]                                                        Yes[@b100-ceor-3-117]                                                        Yes[@b100-ceor-3-117]                      Yes[@b100-ceor-3-117]                      Yes[@b100-ceor-3-117]                      Not specified

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b44-ceor-3-117],[@b101-ceor-3-117]                                                                                                                                        Pharmaceuticals -- Outpatient-- Inpatient[@b102-ceor-3-117]                                                                                            Provide as publicly insured service (reimbursable)[@b44-ceor-3-117]                                                                                 Yes[@b103-ceor-3-117]                                                        Yes[@b99-ceor-3-117]                                                         Yes[@b99-ceor-3-117]                       Yes[@b99-ceor-3-117]                       Yes[@b99-ceor-3-117]                       No[@b99-ceor-3-117]

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                                                                        Pharmaceuticals -- Outpatient-- Inpatient[@b30-ceor-3-117]                                                                                             Provide as publicly insured service (reimbursable)[@b30-ceor-3-117]                                                                                 Yes[@b104-ceor-3-117]                                                        No[@b104-ceor-3-117]                                                         Yes[@b104-ceor-3-117]                      Yes[@b104-ceor-3-117]                      Yes[@b99-ceor-3-117]                       No[@b99-ceor-3-117]

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117]--[@b107-ceor-3-117]                                                                                                Pharmaceuticals -- Outpatient-- Inpatient[@b102-ceor-3-117]                                                                                            Provide as publicly insured service (reimbursable)[@b102-ceor-3-117]Do not provide as publicly funded service (nonreimbursable)[@b102-ceor-3-117]   Yes[@b106-ceor-3-117]                                                        Yes[@b106-ceor-3-117]                                                        Yes[@b102-ceor-3-117]                      Yes[@b102-ceor-3-117]                      Yes[@b102-ceor-3-117]                      Not specified

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                                                                                                              Pharmaceuticals -- Outpatient-- Inpatient[@b108-ceor-3-117]                                                                                            Provide as publicly funded service (reimbursable)[@b108-ceor-3-117]Do not provide as publicly funded service (non-reimbursable)[@b108-ceor-3-117]   Yes[@b21-ceor-3-117]                                                         Yes[@b21-ceor-3-117]                                                         Yes[@b21-ceor-3-117]                       Yes[@b21-ceor-3-117]                       Yes[@b21-ceor-3-117]                       No[@b21-ceor-3-117]

  Sweden            Dental and Pharmaceutical Benefits Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117],[@b110-ceor-3-117]                                                                                                                         Pharmaceuticals -- OutpatientDevices (for administration of pharmaceuticals)[@b15-ceor-3-117],[@b21-ceor-3-117],[@b33-ceor-3-117],[@b109-ceor-3-117]   Provide as publicly funded service (reimbursable)[@b15-ceor-3-117]                                                                                  Yes[@b111-ceor-3-117]                                                        Yes[@b112-ceor-3-117]                                                        Yes[@b109-ceor-3-117]                      Yes[@b109-ceor-3-117]                      Yes[@b109-ceor-3-117]                      Yes[@b109-ceor-3-117]

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117]--[@b115-ceor-3-117]                                                                                                    Pharmaceuticals -- Outpatient-- Inpatient[@b113-ceor-3-117]                                                                                            Provide as publicly funded service (reimbursable)[@b113-ceor-3-117]                                                                                 Yes[@b113-ceor-3-117],[@b114-ceor-3-117]                                     Yes[@b113-ceor-3-117],[@b114-ceor-3-117]                                     Yes[@b113-ceor-3-117],[@b114-ceor-3-117]   Yes[@b113-ceor-3-117],[@b114-ceor-3-117]   Yes[@b113-ceor-3-117],[@b114-ceor-3-117]   Not specified

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Medicinal Products Reimbursement Committee of the Dutch Healthcare Insurance Board (recommendations)[@b116-ceor-3-117]                                                             Pharmaceuticals -- Outpatient-- High cost Inpatient[@b49-ceor-3-117]Procedures[@b117-ceor-3-117]                                                       Provide as publicly funded service (reimbursable)[@b49-ceor-3-117]                                                                                  Yes[@b117-ceor-3-117],[@b118-ceor-3-117]                                     No[@b31-ceor-3-117]                                                          Yes[@b31-ceor-3-117]                       Yes[@b31-ceor-3-117]                       Yes[@b119-ceor-3-117]                      Yes[@b119-ceor-3-117]

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                                                                  Pharmaceuticals -- Outpatient-- Inpatient[@b7-ceor-3-117]Devices[@b7-ceor-3-117]Procedures[@b7-ceor-3-117]                                             Provide as publicly funded service (reimbursable)[@b7-ceor-3-117]                                                                                   Yes[@b7-ceor-3-117]                                                          No[@b7-ceor-3-117]                                                           Yes[@b7-ceor-3-117]                        Yes[@b7-ceor-3-117]                        Yes[@b7-ceor-3-117]                        Yes[@b7-ceor-3-117]

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b120-ceor-3-117]                                                                                                           Pharmaceuticals -- Outpatient-- Inpatient[@b120-ceor-3-117]                                                                                            Provide as publicly funded service (reimbursable)[@b120-ceor-3-117]                                                                                 Yes[@b120-ceor-3-117]                                                        No[@b120-ceor-3-117]                                                         Yes[@b120-ceor-3-117]                      Yes[@b120-ceor-3-117]                      Yes[@b120-ceor-3-117]                      Yes[@b120-ceor-3-117]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of processes for identifying, selecting, and assessing technologies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                      **Technologies to be considered for review**                                                                                                                                                                                                                     **Health technology assessment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                   Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b58-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b58-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b55-ceor-3-117]Methods should comply with internationally recognized systematic review and economic guidelines[@b55-ceor-3-117]                                                                                                                                                                                   Technical staff within Association of Austrian Social Security Institutions (Department of Pharmaceutical Affairs -- pharmacological and medical-therapeutic assessment; Health Economics Team -- economic assessment)[@b55-ceor-3-117]

  Belgium           Minister of Social Affairs (decisions)Commission on reimbursement of medicines/Drug Reimbursement Committee (CRM) (recommendations)[@b9-ceor-3-117]                                   Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b17-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b17-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b9-ceor-3-117]Methods should comply with internationally recognized systematic review guidelines[@b9-ceor-3-117]                                                                                                                                                                                                  Technical staff within CRM supported by external experts[@b9-ceor-3-117]

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117]                                                                                                                         Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b66-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b65-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b66-ceor-3-117]                                                                                                                                                                                                                                                                                                   Technical staff within State Institute for Drug Control[@b65-ceor-3-117]

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b84-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b84-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b68-ceor-3-117]Methods must comply with "Danish guidelines for the socioeconomic analysis of medicines"[@b68-ceor-3-117]                                                                                                                                                                                          Technical staff within Danish Medicines Agency supported by external experts, if necessary[@b68-ceor-3-117]

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                   Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b72-ceor-3-117]                                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b72-ceor-3-117]                                                                                                                                                                                                                                                                                                   Technical staff within Estonian Health Insurance Fund and State Agency of Medicines[@b72-ceor-3-117]

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]           Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b76-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b73-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b122-ceor-3-117]Methods must comply with guidelines of the Ministry of Social Affairs and Health[@b122-ceor-3-117]                                                                                                                                                                                                Technical staff within Pharmaceuticals Pricing Board supported by external experts[@b122-ceor-3-117]

  France            Ministry for Health and Social Security (decisions)[@b21-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                         *Depends on type of appraisal1*[@b6-ceor-3-117],[@b20-ceor-3-117]\                                                                                                                                                                                               *Single technology appraisals*Typically considered in order received[@b16-ceor-3-117]*Multiple technology appraisals*Selection criteria not specified                                                                                                                                                                                   *Single technology appraisals*Manufacturer through submission requirements[@b20-ceor-3-117]*Multiple technology appraisals*Technical staff within Health and Social Security supported by external experts[@b20-ceor-3-117]Methods should comply with internationally recognized systematic review and economic guidelines[@b20-ceor-3-117]                     *Single technology appraisals*Technical staff within Health and Social Security supported by external experts[@b20-ceor-3-117]*Multiple technology appraisals*Technical staff within Health and Social Security or independent academic group[@b20-ceor-3-117]
                                                                                                                                                                                                          *Single technology appraisal*\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                          Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals and devicesHealth care professional associations seeking reimbursement for procedures*Multiple technology appraisals*\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                          *Typically classes of pharmaceuticals or categories of devices*\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                          *Referred by:*Health care professional associationsMinistry of HealthNational Union of Health Insurance FundsPatient and/or carer organizations[@b120-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117]                                            Referred by: Associations represented by Federal Joint CommitteeMinistry of HealthInstitute for Quality and Efficiency in Health CareFederal commissioner of patient affairsPatient and/or carer organizations[@b18-ceor-3-117]                                  Determined by Federal Joint CommitteeSelection criteria: Clinical relevanceCost implications"Risks"[@b6-ceor-3-117]                                                                                                                                                                                                                     Technical staff within Institute for Quality and Efficiency in Health Care supported by external experts[@b123-ceor-3-117],[@b124-ceor-3-117]Methods must comply with Institute for Quality and Efficiency in Health Care systematic review and economic guidelines[@b124-ceor-3-117]                                                                           Technical staff within Institute for Quality and Efficiency in Health Care supported by external experts[@b123-ceor-3-117],[@b124-ceor-3-117]

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117]                                                                                 Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b85-ceor-3-117]                                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b85-ceor-3-117]                                                                                                                                                                                                                                                                                                   Technical staff within Transparency Committee in the Reimbursement and Medicinal Products[@b85-ceor-3-117]

  Hungary           Ministers of Health and Finance (decisions)National Health Insurance Fund Administration (recommendations)[@b88-ceor-3-117],[@b89-ceor-3-117]                                         Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticalsNational Health Insurance Fund Administration[@b88-ceor-3-117]                                                                                                                Not specified                                                                                                                                                                                                                                                                                                                           Technical staff within National Technology Assessment Office of the National Institute for Strategic Health Research[@b90-ceor-3-117]                                                                                                                                                                                                                           Technical staff within National Technology Assessment Office of the National Institute for Strategic Health Research[@b90-ceor-3-117]

  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                                               Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b91-ceor-3-117]\                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b93-ceor-3-117],[@b125-ceor-3-117]Methods must comply with Irish Health Technology Assessment Guidelines[@b93-ceor-3-117]                                                                                                                                                                                         Technical staff within National Centre for Pharmacoeconomics, supported by external clinical experts[@b93-ceor-3-117]
                                                                                                                                                                                                          Referred by: Department of Health and Children of the Health Services Executive for new and existing devices and diagnostic tests that might "incur a high cost or have a significant budget impact"[@b91-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]   Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b27-ceor-3-117]                                                                                                                                                             Typically considered in order received[@b27-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b126-ceor-3-117]Methods must comply with Italian submission guidelines[@b27-ceor-3-117]                                                                                                                                                                                                                           Members of Technical Scientific Committee[@b126-ceor-3-117]

  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]                                                             Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b34-ceor-3-117]                                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b34-ceor-3-117]Methods should comply with internationally recognized systematic review guidelines[@b34-ceor-3-117]                                                                                                                                                                                                Technical staff within Norwegian Medicines Agency and Department of Pharmacoeconomics[@b98-ceor-3-117]

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117]                                                                                                                                       Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b99-ceor-3-117]                                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b99-ceor-3-117]                                                                                                                                                                                                                                                                                                   Technical staff within Ministry of Health[@b99-ceor-3-117]Agency for Health Technology Assessment[@b127-ceor-3-117]

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b36-ceor-3-117],[@b45-ceor-3-117]                                                                                           Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b36-ceor-3-117]                                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b36-ceor-3-117]                                                                                                                                                                                                                                                                                                   Technical staff within INFARMED supported by external experts[@b36-ceor-3-117]

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                          Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b104-ceor-3-117]Automatic within 12 weeks of market launch[@b104-ceor-3-117]                                                                                                Exclusion criteria: Already appraised by National Institute of Health and Clinical Excellence through its multiple technologies appraisal process[@b104-ceor-3-117]                                                                                                                                                                     Manufacturer through submission requirements[@b128-ceor-3-117]Methods must comply with Scottish Medicines Consortium systematic review and economic guidelines[@b34-ceor-3-117]                                                                                                                                                                                 Technical staff within Scottish Medicines Consortium supported by external experts[@b128-ceor-3-117]

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b107-ceor-3-117],[@b129-ceor-3-117],[@b106-ceor-3-117]             Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b104-ceor-3-117]                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b131-ceor-3-117]                                                                                                                                                                                                                                                                                                  Working group for pharmacoeconomics and outcomes research[@b131-ceor-3-117]

  Spain             Ministry of Health Directorate General of Pharmacy and Health ProductsInter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                            Referred by: Ministry of Health (newly approved pharmaceuticals)[@b108-ceor-3-117]                                                                                                                                                                               Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through invitation to submit information to Inter-Ministerial Pricing Commission[@b21-ceor-3-117]Technical staff within Ministry of Health[@b132-ceor-3-117]                                                                                                                                                                                       Inter-Ministerial Pricing Commission[@b21-ceor-3-117]

  Sweden            Dental and Pharmaceutical Benefits Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117],[@b110-ceor-3-117]                                                                           Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b104-ceor-3-117]Dental and Pharmaceutical Benefits Board (for pharmaceuticals approved prior to 2002)[@b133-ceor-3-117],[@b134-ceor-3-117]                                  For new pharmaceuticals: typically considered in order receivedFor older pharmaceuticals: Overall sales volume[@b134-ceor-3-117],[@b135-ceor-3-117]                                                                                                                                                                                     For new pharmaceuticals: Manufacturer through submission requirements[@b136-ceor-3-117]For older pharmaceuticals: Technical staff within Dental and Pharmaceutical Benefits Board supported by external experts[@b136-ceor-3-117]Methods must comply with Dental and Pharmaceutical Benefits Board systematic review and economic guidelines[@b10-ceor-3-117]   For new pharmaceuticals: Technical staff within Dental and Pharmaceutical Benefits Board[@b136-ceor-3-117]For older pharmaceuticals: Technical staff within Dental and Pharmaceutical Benefits Board supported by external experts[@b136-ceor-3-117]

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b114-ceor-3-117],[@b115-ceor-3-117]                                                       Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b114-ceor-3-117]Patients and carersHospitals and hospital groupsHealth care professional associationsFederal Office of Public Health[@b114-ceor-3-117],[@b137-ceor-3-117]   Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b113-ceor-3-117]                                                                                                                                                                                                                                                                                                  Federal Drug Commission[@b114-ceor-3-117]

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Medicinal Products Reimbursement Committee of the Dutch Healthcare Insurance Board (recommendations)[@b116-ceor-3-117]               Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b31-ceor-3-117]University hospital federations, health care professional associations, and Dutch Healthcare Insurance Board for high-cost inpatient pharmaceuticals         Not specified                                                                                                                                                                                                                                                                                                                           Manufacturer through submission requirements[@b31-ceor-3-117]Technical staff within Dutch Healthcare Insurance Board[@b117-ceor-3-117]Methods must comply with internationally recognize systematic review guidelines and Dutch Healthcare Insurance Board economic guidelines[@b117-ceor-3-117]                                                                Technical staff within Dutch Healthcare Insurance Board[@b117-ceor-3-117]

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                    Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticalsPatients and carersHealth care providersHealth care professional associationsGeneral PublicNational Horizon Scanning Centre[@b120-ceor-3-117]                                 Selection criteria: Burden of disease (population affected, mortality, and morbidity)Resource impact (on National Health Service costs and resources)Clinical importancePolicy importance (alignment with government priority areas)Inappropriate variations in practiceLikelihood of national guidance adding value[@b7-ceor-3-117]\   *Single technology appraisals*Manufacturer through submission requirements[@b120-ceor-3-117]Multiple technology appraisals Independent academic group[@b120-ceor-3-117]Methods must comply with National Institute for Health and Clinical Excellence systematic review and economic guidelines[@b120-ceor-3-117]                                               *Single technology appraisals*Independent academic group[@b120-ceor-3-117]Multiple technology appraisals Independent academic group[@b120-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Technology selection panel composition: Health care providers (specialists, general practitioners, and public health professionals)Patient representatives Technology selection panel makes recommendations. Final decisions made by Department of Health[@b7-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                               

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b28-ceor-3-117]                                                              Referred by: Manufacturers seeking reimbursement for newly approved pharmaceuticals[@b28-ceor-3-117]Welsh Medicines Partnership horizon scanning process for identifying pharmaceuticals expected to receive market approval within 18 months[@b28-ceor-3-117]   Typically considered in order received[@b28-ceor-3-117]                                                                                                                                                                                                                                                                                 Manufacturer through submission requirements[@b28-ceor-3-117]Welsh Medicines Partnership[@b28-ceor-3-117]Methods must comply with All Wales Medicines Strategy Group systematic review and economic guidelines[@b28-ceor-3-117]                                                                                                                                 Welsh Medicines Partnership[@b28-ceor-3-117]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of clinical evidence requirements

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                      **Clinical evidence requirements**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                   Target patient population and indications (therapeutic claim)PharmacologySafetyEfficacyEffectiveness (across population subgroups)Frequency and duration of treatment[@b55-ceor-3-117]                                                          Not specified                                                                                                                                                                                                                                                                                                                                    Preference for: Double-blind randomized controlled trialsSystematic reviews and meta-analyses of randomized controlled trials complying with internationally recognized guidelines[@b55-ceor-3-117]                                                                                                                                                                                                                                                                                             Published, peer-reviewed studiesUnpublished reports and studies may be accepted in exceptional circumstances[@b55-ceor-3-117]Commercial, in-confidence data[@b55-ceor-3-117]

  Belgium           Minister of Social Affairs (decisions)Commission on reimbursement of medicines/Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]                       Target patient population and indications (therapeutic claim)SafetyEfficacyEffectiveness (across population subgroups)[@b11-ceor-3-117]                                                                                                         MorbidityAdverse events/complicationsQuality of lifeOverall survival/mortality (life-years gained)Quality-adjusted life years (QALYs) -- measured in patients but valued by public/societyOther relevant disease-specific outcomes[@b4-ceor-3-117]Final endpoints[@b11-ceor-3-117]                                                               Preference for: Randomized controlled trialsObservational head-to-head comparative studies[@b11-ceor-3-117],[@b17-ceor-3-117]Effectiveness studies (over efficacy studies)[@b17-ceor-3-117]Minimum of one positive superiority trial on primary endpoints against active control or placebo (if no alternative treatments exist)[@b17-ceor-3-117]                                                                                                                                               Published, peer-reviewed studiesUnpublished reports and studies[@b17-ceor-3-117]Abstracts not accepted[@b9-ceor-3-117]

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117]                                                                                                                         SafetyEfficacyEffectiveness[@b66-ceor-3-117]                                                                                                                                                                                                    Not specified                                                                                                                                                                                                                                                                                                                                    All clinical trials[@b138-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not specified

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                Target patient population and indications (therapeutic claim)SafetyEfficacyEffectiveness (across population subgroups)[@b38-ceor-3-117]                                                                                                         Not specified                                                                                                                                                                                                                                                                                                                                    Preference for: Randomized controlled trials comparing pharmaceutical to standard care[@b38-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                         Not specified

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b67-ceor-3-117]                                                                   SafetyEfficacyEffectiveness[@b139-ceor-3-117]                                                                                                                                                                                                   Adverse events/complicationsSide effectsOverall survival/mortality[@b139-ceor-3-117],[@b140-ceor-3-117]                                                                                                                                                                                                                                          Preference for: Randomized controlled trials[@b84-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                   Published, peer-reviewed studies[@b84-ceor-3-117]

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]           Target patient population and indications (therapeutic claim)Severity and burden of illnessEffectiveness (across population subgroups)[@b76-ceor-3-117]                                                                                         Not specified                                                                                                                                                                                                                                                                                                                                    Preference for: Randomized controlled trials comparing pharmaceutical to standard care[@b76-ceor-3-117]*Evidence from other available direct comparative experimental and observational studies, as well as meta-analyses, should be included*[@b76-ceor-3-117]                                                                                                                                                                                                                                 Published, peer-reviewed studies[@b76-ceor-3-117]

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b20-ceor-3-117],[@b78-ceor-3-117]       Target patient population and indications (therapeutic claim)Current managementPlace of technology in care pathwaySafetyEfficacyEffectiveness (across population subgroups)[@b16-ceor-3-117]                                                    MorbidityOverall survival/mortalityQuality of life[@b16-ceor-3-117]                                                                                                                                                                                                                                                                              Preference for: Head-to-head, double-blind randomized controlled trialsOther direct comparative studiesPost-market studiesSystematic reviews and meta-analyses of randomized controlled trials complying with internationally recognized guidelines[@b16-ceor-3-117]                                                                                                                                                                                                                            Published, peer-reviewed studiesCurrent national and international clinical practice guidelinesExpert opinionSurveys of practiceCommercial, in-confidence data[@b16-ceor-3-117]

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117],[@b141-ceor-3-117]                         Target patient population and indications (therapeutic claim)Severity and burden of illnessSafetyEfficacyEffectiveness (across population subgroups)[@b8-ceor-3-117]                                                                            MorbidityOverall survival/mortalityQuality of lifeAdverse events/complicationsSide effectsDuration of illnessHealth status[@b8-ceor-3-117],[@b83-ceor-3-117],[@b142-ceor-3-117]--[@b144-ceor-3-117]Topic specific outcomes identified in consultation with patient organizations[@b18-ceor-3-117]Validated surrogate outcomes[@b83-ceor-3-117]   Preference for: Randomized controlled trials comparing pharmaceutical to placebo, standard care, or no active treatment[@b8-ceor-3-117]\                                                                                                                                                                                                                                                                                                                                                        Published, peer-reviewed studiesCommercial, in-confidence data not accepted unless it can be published[@b18-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           *Evidence from other available direct comparative experimental and observational studies, as well as systematic reviews and meta-analyses complying with internationally recognized guidelines, should also be included*[@b8-ceor-3-117]If no treatment alternative exists, well-documented case series acceptable[@b8-ceor-3-117]                                                                                                                                                              

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117]                                                                                 SafetyEfficacyEffectiveness[@b145-ceor-3-117]                                                                                                                                                                                                   Not specified                                                                                                                                                                                                                                                                                                                                    Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Not specified

  Hungary           Ministers of Health and Finance (decisions)National Health Insurance Fund Administration (recommendations)[@b88-ceor-3-117]                                                           Severity and burden of illnessCurrent managementSafetyEfficacyEffectiveness (across population subgroups)[@b90-ceor-3-117]                                                                                                                      Not specified                                                                                                                                                                                                                                                                                                                                    Preference for: Randomized controlled trials[@b84-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                   Published, peer-reviewed studies[@b90-ceor-3-117]

  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                                               SafetyEfficacyEffectiveness (across population subgroups)[@b146-ceor-3-117]                                                                                                                                                                     MorbidityOverall survival/mortalityQuality of lifeQALYs -- measured in patients but valued by public/society[@b146-ceor-3-117]All other health benefits accrued by individuals[@b147-ceor-3-117]                                                                                                                                                 Preference for: Randomized controlled trials[@b147-ceor-3-117]*Evidence from other available direct comparative experimental and observational studies, as well as systematic reviews and meta-analyses complying with Irish Health Technology Assessment Guidelines, should also be included*[@b146-ceor-3-117]                                                                                                                                                                                Not specified

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]   Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementSafetyEfficacyEffectiveness (across population subgroups)[@b148-ceor-3-117]                                                        MorbidityOverall survival/mortalityQuality of life[@b149-ceor-3-117]                                                                                                                                                                                                                                                                             Preference for: Randomized controlled trials comparing pharmaceutical to standard care[@b97-ceor-3-117]Evidence from other available direct experimental and observational studies comparing pharmaceutical with standard care[@b148-ceor-3-117]                                                                                                                                                                                                                                                Not specified

  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]                                                             Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementPlace of technology in care pathwaySafetyEfficacyEffectiveness (across population subgroups)[@b34-ceor-3-117],[@b149-ceor-3-117]   MorbidityOverall survival/mortalityQuality of life[@b144-ceor-3-117]                                                                                                                                                                                                                                                                             Preference for: Head-to-head, double-blind randomized controlled trialsOther direct comparative studiesSystematic reviews and meta-analyses complying with internationally recognized guidelines[@b149-ceor-3-117],[@b150-ceor-3-117]                                                                                                                                                                                                                                                           Published, peer-reviewed studiesUnpublished reports and studies[@b149-ceor-3-117],[@b150-ceor-3-117]

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117],[@b100-ceor-3-117]                                                                                                                    Severity and burden of illnessCurrent managementSafetyEfficacyEffectiveness (across population subgroups)[@b151-ceor-3-117]                                                                                                                     MorbidityOverall survival/mortalityQuality of life[@b151-ceor-3-117]                                                                                                                                                                                                                                                                             Preference for: Randomized controlled trials[@b151-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                  Published, peer-reviewed studiesUnpublished reports and studies[@b151-ceor-3-117]

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b44-ceor-3-117]                                                                                                             SafetyEfficacyEffectiveness (across population subgroups)[@b101-ceor-3-117]                                                                                                                                                                     MorbidityOverall survival/mortalityQuality of life[@b101-ceor-3-117]                                                                                                                                                                                                                                                                             Preference for: Effectiveness studies of target population (over efficacy studies)[@b101-ceor-3-117]Comparative clinical trialsOther study designs accepted, but rationale must be provided[@b101-ceor-3-117]                                                                                                                                                                                                                                                                                   Not specified

  Scotland          National Health Service Scotland (decisions)[@b50-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                          Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementPlace of technology in care pathway"Comparative" safetyEfficacyEffectiveness (across population subgroups)[@b128-ceor-3-117]       MorbidityOverall survival/mortalityQuality of lifeQALYs (strongly preferred)[@b50-ceor-3-117]                                                                                                                                                                                                                                                    Randomized controlled trials requiredComparative observational studies accepted[@b50-ceor-3-117]If no head-to head studies available, indirect comparison required[@b50-ceor-3-117]                                                                                                                                                                                                                                                                                                             Published, peer-reviewed studiesUnpublished reports and studiesExpert opinionSubmissions from patient and carer organizations[@b128-ceor-3-117]

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b107-ceor-3-117],[@b130-ceor-3-117]                                Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementPatient acceptanceSafetyEfficacyEffectivenessFrequency and duration of treatment[@b106-ceor-3-117]                                 MorbidityOverall survival/mortalityAdverse events/complicationsQuality of life[@b106-ceor-3-117]                                                                                                                                                                                                                                                 Preference for: Comparative studies[@b84-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                            Published, peer-reviewed studiesUnpublished reports and studies with negative findings[@b152-ceor-3-117]

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                          Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementSafetyEfficacyEffectiveness[@b132-ceor-3-117]                                                                                      MorbidityOverall survival/mortalityQuality of lifeQALYs[@b132-ceor-3-117]                                                                                                                                                                                                                                                                        Preference for: Randomized controlled trials*Evidence from other available direct comparative experimental and observational studies should also be included*[@b132-ceor-3-117]                                                                                                                                                                                                                                                                                                                 Not specified

  Sweden            Dental and Pharmaceutical Benefits Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117]                                                                                              Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementSafetyEfficacyEffectiveness[@b153-ceor-3-117]                                                                                      MorbidityOverall survival/mortalityQuality of lifeQALYs (preferred)[@b109-ceor-3-117]                                                                                                                                                                                                                                                            Preference for: Randomized controlled trials comparing pharmaceutical to standard care[@b109-ceor-3-117]*Evidence from other available direct comparative experimental and observational studies should also be included*[@b15-ceor-3-117]                                                                                                                                                                                                                                                      Commercial, in-confidence data[@b109-ceor-3-117]Published, peer-reviewed studiesUnpublished reports and studiesOngoing studiesSubmissions from patient and carer organizations[@b51-ceor-3-117]

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117]--[@b115-ceor-3-117]                                                      SafetyEfficacyEffectiveness[@b113-ceor-3-117]                                                                                                                                                                                                   Not specified                                                                                                                                                                                                                                                                                                                                    Not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Not specified

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Medicinal Products Reimbursement Committee of the Dutch Healthcare Insurance Board (recommendations)[@b116-ceor-3-117]               Target patient population and indications (therapeutic claim)Severity and burden of illnessSafetyEfficacyEffectiveness[@b154-ceor-3-117]                                                                                                        MorbidityOverall survival/mortalityQuality of life[@b36-ceor-3-117],[@b155-ceor-3-117]                                                                                                                                                                                                                                                           Preference for: Head-to-head randomized controlled trialsSystematic reviews or meta-analyses complying with internationally recognized guidelines[@b35-ceor-3-117],[@b156-ceor-3-117]                                                                                                                                                                                                                                                                                                           Published, peer-reviewed studiesUnpublished reports and studiesCommercial, in-confidence dataExpert opinion[@b154-ceor-3-117]

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                    Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementPlace of technology in care pathway"Comparative" safetyEfficacyEffectiveness (across population subgroups)[@b29-ceor-3-117]        MorbidityOverall survival/mortality (life years)Quality of life[@b157-ceor-3-117]QALYs -- measured in patients but valued by public/society[@b29-ceor-3-117],[@b158-ceor-3-117]                                                                                                                                                                  Preference for: Head-to-head randomized controlled trials conducted in "naturalistic" settingsEffectiveness studies of target population (over efficacy studies)Systematic reviews or meta-analyses complying with internationally recognized guidelines[@b159-ceor-3-117]*Evidence from other available direct comparative experimental and observational studies should also be included*[@b159-ceor-3-117]*Registries, case series, and follow-up studies also accepted*[@b159-ceor-3-117]   Published, peer-reviewed studiesUnpublished reports and studiesCommercial, in-confidence data[@b159-ceor-3-117]Submissions from patient and carer organizations[@b159-ceor-3-117]Information from health care professional associations, administrators, government, and manufacturers[@b157-ceor-3-117]

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b120-ceor-3-117]                                                             Target patient population and indications (therapeutic claim)Severity and burden of illnessCurrent managementPlace of technology in care pathway"Comparative" safetyEfficacyEffectiveness (across population subgroups)[@b28-ceor-3-117]        MorbidityOverall survival/mortalityQuality of lifeQALYs (preferred)[@b28-ceor-3-117]                                                                                                                                                                                                                                                             All types of clinical studies accepted, but greater importance given to high quality ones[@b28-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                      Published, peer-reviewed studiesUnpublished reports and studiesExpert opinionSubmissions from patient and carer organizations describing experiences of those who have taken the pharmaceutical[@b28-ceor-3-117]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of economic evidence requirements

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                      **Economic analysis**                                                                                                                                                            **Budget impact analysis**                                                                                                                                                                                                                                                                                              **Other economic information**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                   Yes for: "innovative products providing substantial therapeutic benefit"where no comparable medical preparation exists"[@b21-ceor-3-117]                                         Any type, but rationale for selection must be provided[@b21-ceor-3-117]Should comply with internationally recognized pharmacoeconomic guidelines[@b21-ceor-3-117]                                                                                                                                                       Payer[@b21-ceor-3-117]Costs not specified                                                                                                                                                                          Most commonly used alternative[@b21-ceor-3-117]                                                                                                                                                                      Yes -- type not specified[@b21-ceor-3-117]                                                                 Yes                                        No information found                                                            N/A                                                                                                                               3 year market sales forecastPrice in other European Union countriesReimbursement status in other European Union countries[@b55-ceor-3-117]

  Belgium           Minister of Social Affairs (decisions)Commission on reimbursement of medicines/drug reimbursement committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]                       Yes for: Pharmaceuticals with added therapeutic value relative to existing alternatives (Class I)[@b11-ceor-3-117],[@b17-ceor-3-117]\                                            Cost effectivenessCost utilityCost benefit not accepted[@b11-ceor-3-117]Should comply with Belgium pharmacoeconomic guidelines[@b17-ceor-3-117]                                                                                                                                                                         Payer (includes patient copayments and government)[@b11-ceor-3-117],[@b17-ceor-3-117]Direct costs only[@b11-ceor-3-117],[@b17-ceor-3-117]                                                                          Most commonly used alternative ORAlternative most likely to be replacedIf add-on: current treatment without add-on[@b17-ceor-3-117]Off-label treatments not acceptable[@b11-ceor-3-117] Rationale must be provided   Probabilistic[@b17-ceor-3-117]                                                                             Yes[@b17-ceor-3-117]                       Yes[@b11-ceor-3-117]                                                            Direct costs only[@b11-ceor-3-117],[@b17-ceor-3-117]                                                                              PriceReimbursement status in other European Union countries[@b11-ceor-3-117],[@b17-ceor-3-117]
                                                                                                                                                                                                          Not required for orphan pharmaceuticals[@b62-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117]                                                                                                                         Yes[@b66-ceor-3-117]                                                                                                                                                             Cost effectiveness[@b138-ceor-3-117]                                                                                                                                                                                                                                                                                    Payer[@b66-ceor-3-117]Direct costs[@b138-ceor-3-117]                                                                                                                                                               No information found                                                                                                                                                                                                 Method not specified                                                                                       No information found                       Yes[@b138-ceor-3-117]                                                           No information found                                                                                                              No information found

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                No, but often included to justify high price[@b68-ceor-3-117],[@b71-ceor-3-117],[@b160-ceor-3-117]                                                                               Cost effectivenessCost utility[@b68-ceor-3-117]\                                                                                                                                                                                                                                                                        Societal (if included)Direct, indirect, and intangible; to be reported separately[@b71-ceor-3-117]                                                                                                                 Most commonly used alternative[@b38-ceor-3-117]                                                                                                                                                                      Method not specified, but key parameters associated with uncertainty should be explored[@b38-ceor-3-117]   No information found                       Yes[@b38-ceor-3-117]                                                            No information found                                                                                                              Reimbursement status in other European Union countriesEstimated consumption (number of patients and utilization)[@b38-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                           If included, methods should comply with Danish Guidelines for the Socio-economic Analysis of Medicines[@b68-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                   Yes[@b84-ceor-3-117],[@b139-ceor-3-117]                                                                                                                                          Cost effectivenessCost utilityCost minimization rationale for selection must be provided[@b139-ceor-3-117]                                                                                                                                                                                                              Payer[@b139-ceor-3-117]May present separate analysis from societal perspective[@b84-ceor-3-117]Direct costs within and outside of the health care system (should be reported separately)[@b139-ceor-3-117]         Most commonly used alternative ORStandard care[@b139-ceor-3-117] Rationale must be provided                                                                                                                          Method not specified                                                                                       No information found                       No information found                                                            No information found                                                                                                              No information found

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]           Yes for:\                                                                                                                                                                        Any type, but rationale for selection must be provided[@b76-ceor-3-117]Methods must comply with Ministry of Social Affairs and Health guidelines[@b76-ceor-3-117]                                                                                                                                                       Societal[@b76-ceor-3-117]Direct and indirect costs -- presented separately[@b76-ceor-3-117]                                                                                                                        Alternative most likely to be replaced ORMost commonly used alternative ORMost effective alternative ORMinimum management[@b76-ceor-3-117] Rationale must be provided                                                Method not specified                                                                                       Yes[@b76-ceor-3-117]                       Yes[@b161-ceor-3-117]                                                           No information found                                                                                                              Market sales forecastReimbursement status in other European Union countriesEstimated consumption (number of patients and utilization)[@b161-ceor-3-117]
                                                                                                                                                                                                          Pharmaceuticals considered for reimbursement in one of the special refund categories[@b74-ceor-3-117],[@b76-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                         Yes for: Multiple technology appraisals of pharmaceuticals[@b20-ceor-3-117]                                                                                                      Any type, but rationale for selection must be provided[@b22-ceor-3-117]Methods must comply with French economic guidelines[@b20-ceor-3-117]                                                                                                                                                                             Varies, but should take the widest possible perspective -- rationale for selection must be provided [@b84-ceor-3-117]Direct costs; may include indirect costs, but must be presented separately[@b22-ceor-3-117]   Following 3 comparators required: Most commonly used alternativeMost recently reimbursed alternativeLeast expensive alternative[@b16-ceor-3-117]                                                                     Method not specified                                                                                       Yes for pharmaceuticals[@b22-ceor-3-117]   Yes[@b20-ceor-3-117]                                                            No information found                                                                                                              Market sales forecastReimbursement status in other European Union countriesBreakdown of costs for manufacturing and distribution[@b22-ceor-3-117],[@b162-ceor-3-117]

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117],[@b24-ceor-3-117],[@b144-ceor-3-117]       Yes for: Technologies where alternative treatment exists[@b8-ceor-3-117],[@b18-ceor-3-117]                                                                                       Any one of: Cost effectivenessCost utilityCost minimization/cost comparison[@b18-ceor-3-117]\                                                                                                                                                                                                                           PayerPatient[@b83-ceor-3-117]Direct and indirect costs[@b8-ceor-3-117]                                                                                                                                             Most commonly used alternative ORMost effective alternative ORMinimum standard care[@b8-ceor-3-117]                                                                                                                  One-way and multi-way (performed as probabilistic)[@b24-ceor-3-117]                                        Yes[@b84-ceor-3-117]                       Yes, except when no alternative exists[@b18-ceor-3-117]                         No information found                                                                                                              No information found
                                                                                                                                                                                                                                                                                                                                                                                           Efficiency frontier analysis[@b12-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117],[@b160-ceor-3-117]                                                              Yes for: Pharmaceuticals eligible for reference price system[@b85-ceor-3-117]                                                                                                    No information found                                                                                                                                                                                                                                                                                                    No information found                                                                                                                                                                                               No information found                                                                                                                                                                                                 No information found                                                                                       No information found                       Yes[@b85-ceor-3-117]                                                            No information found                                                                                                              Cost of daily treatmentReimbursement status in other European Union countries[@b85-ceor-3-117]

  Hungary           Ministers of Health and Finance (decisions)National Health Insurance Fund Administration (recommendations)[@b86-ceor-3-117],[@b90-ceor-3-117],[@b102-ceor-3-117]                      Yes[@b84-ceor-3-117]                                                                                                                                                             Preference for: Cost effectivenessCost utility[@b163-ceor-3-117]                                                                                                                                                                                                                                                        PayerSocietal (also recommended) Report results from each perspective separately[@b163-ceor-3-117]                                                                                                                 Standard care[@b163-ceor-3-117]                                                                                                                                                                                      Yes, but type not specified[@b163-ceor-3-117]                                                              No information found                       Yes[@b84-ceor-3-117]                                                            If payer perspective, include direct costs onlyIf societal perspective, include indirect costs (productivity)[@b163-ceor-3-117]   No information found

  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                                               Yes[@b146-ceor-3-117]                                                                                                                                                            Preference for: Cost utility[@b10-ceor-3-117]\                                                                                                                                                                                                                                                                          Payer[@b147-ceor-3-117]Direct costs only[@b147-ceor-3-117]                                                                                                                                                         Standard care[@b125-ceor-3-117]                                                                                                                                                                                      Probabilistic and deterministic[@b125-ceor-3-117]                                                          No information found                       Yes                                                                             Direct costs only[@b91-ceor-3-117],[@b147-ceor-3-117]                                                                             No information found
                                                                                                                                                                                                                                                                                                                                                                                           Any one of the following may be acceptable if rationale is provided: Cost benefitCost effectivenessCost minimization/cost comparison[@b147-ceor-3-117],[@b165-ceor-3-117]Methods must comply with Irish Healthcare Technology Assessment Guidelines[@b146-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]   Yes for: Pharmaceuticals with a favorable "risk/benefit profile"[@b97-ceor-3-117],[@b148-ceor-3-117]                                                                             Preference for: Cost utilityCost effectiveness[@b148-ceor-3-117]Methods must comply with Italian pharmacoeconomic guidelines[@b148-ceor-3-117]                                                                                                                                                                          Societal ANDPayer[@b148-ceor-3-117]Direct and indirect costs[@b148-ceor-3-117]                                                                                                                                     Most commonly used alternative[@b148-ceor-3-117]                                                                                                                                                                     Methods not specified, but should involve multi-way analysis[@b148-ceor-3-117]                             No information found                       Yes[@b148-ceor-3-117]                                                           No information found                                                                                                              Cost of treatment compared to those in same therapeutic classMarket sales forecastPrice in other European Union countriesReimbursement status in other European Union countriesEstimated consumption (number of patients and utilization)Industrial implications[@b97-ceor-3-117]

  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmaco economics (recommendations)[@b98-ceor-3-117]                                                            Yes for: Pharmaceuticals with added therapeutic value relative to existing alternatives[@b34-ceor-3-117]                                                                         Preference for: Cost-value analysis[@b150-ceor-3-117]Any one of the following may be acceptable if rationale is provided: Cost benefitCost effectivenessCost utilityCost consequenceCost minimization/cost comparison[@b34-ceor-3-117]Methods must comply with Norwegian pharmacoeconomic guidelines[@b34-ceor-3-117]   Societal ANDPayer[@b150-ceor-3-117]                                                                                                                                                                                Most commonly used alternative ORLeast expensive alternative[@b150-ceor-3-117]                                                                                                                                       Probabilistic preferred[@b150-ceor-3-117]                                                                  No information found                       Yes[@b149-ceor-3-117]\                                                          No information found                                                                                                              Market sales forecastPrice in other European Union countriesReimbursement status in other European Union countriesEstimated consumption (number of patients and utilization)[@b149-ceor-3-117],[@b150-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Aggregate added expense to health service for first 5 years[@b149-ceor-3-117]                                                                                                                                     

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117],[@b166-ceor-3-117]                                                                                                                    Yes for: Pharmaceuticals with added therapeutic value relative to existing alternatives[@b84-ceor-3-117]                                                                         Cost effectivenessCost utility[@b84-ceor-3-117]                                                                                                                                                                                                                                                                         Societal ANDPayer[@b167-ceor-3-117]                                                                                                                                                                                Alternative most likely to be replaced ORMost commonly used alternative ORLeast expensive alternative ORStandard care compliant with clinical practice guidelines[@b151-ceor-3-117]                                  Methods not specified                                                                                      No information found                       Yes[@b84-ceor-3-117]                                                            No information found                                                                                                              No information found

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b64-ceor-3-117],[@b160-ceor-3-117]                                                                                          Yes[@b44-ceor-3-117],[@b160-ceor-3-117]                                                                                                                                          Any one of : Cost benefitCost effectivenessCost utilityCost minimization/cost comparison; rationale for selection must be provided[@b101-ceor-3-117]                                                                                                                                                                    Societal[@b101-ceor-3-117]Direct costsIndirect costs: only those related to lost productivity[@b101-ceor-3-117]                                                                                                    Most commonly used alternativeStandard care[@b101-ceor-3-117]                                                                                                                                                        Methods not specified                                                                                      No information found                       No[@b101-ceor-3-117]                                                            N/A                                                                                                                               No information found

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                          Yes[@b168-ceor-3-117]                                                                                                                                                            Any one of : Cost benefitCost effectivenessCost utilityCost minimization/cost comparison; rationale for selection must be provided[@b168-ceor-3-117]Methods must comply with SMC economic guidelines[@b168-ceor-3-117]                                                                                                  Payer[@b30-ceor-3-117]                                                                                                                                                                                             Alternative most likely to be replaced ORMost commonly used alternative[@b30-ceor-3-117]                                                                                                                             Probabilistic[@b168-ceor-3-117]                                                                            No information found                       Yes[@b30-ceor-3-117]                                                            No information found                                                                                                              National Health Service resource implications[@b30-ceor-3-117]

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b107-ceor-3-117]                                                   Yes[@b105-ceor-3-117],[@b106-ceor-3-117]                                                                                                                                         Cost effectivenessCost utility (if pharmaceutical has impact on quality of life)Cost minimization/cost comparisonCost benefit not accepted[@b169-ceor-3-117]\                                                                                                                                                           Payer[@b169-ceor-3-117]Direct costs[@b169-ceor-3-117]                                                                                                                                                              Alternative most likely to be replacedIf add-on: current treatment without add-on[@b152-ceor-3-117]                                                                                                                  Probabilistic[@b106-ceor-3-117],[@b152-ceor-3-117]                                                         Yes[@b152-ceor-3-117]                      Yes\                                                                            No information found                                                                                                              No information found
                                                                                                                                                                                                                                                                                                                                                                                           Methods should comply with national economic guidelines[@b170-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Estimated over first 5 years[@b84-ceor-3-117]                                                                                                                                                                     

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117],[@b171-ceor-3-117]       No[@b21-ceor-3-117]                                                                                                                                                              Preference for: Cost effectivenessCost utility[@b10-ceor-3-117],[@b21-ceor-3-117]\                                                                                                                                                                                                                                      Societal ANDPayer[@b10-ceor-3-117]Presented separately                                                                                                                                                             Most commonly used alternativeStandard care[@b10-ceor-3-117]Rationale must be provided                                                                                                                               Multi-way[@b10-ceor-3-117]                                                                                 No information found                       Yes, comparing "corresponding products"[@b10-ceor-3-117]                        No information found                                                                                                              No information found
                                                                                                                                                                                                                                                                                                                                                                                           Any one of the following may be acceptable if rationale is provided: Cost benefitCost effectivenessCost utilityCost consequenceCost minimization/cost comparison[@b10-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Sweden            Dental and Pharmaceutical Benefits Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117]                                                                                              Yes, if requested[@b21-ceor-3-117]                                                                                                                                               Any one of: Cost effectivenessCost utilityCost minimization/cost comparison; rationale for selection must be provided[@b15-ceor-3-117]Methods must comply with Swedish economic guidelines[@b15-ceor-3-117]                                                                                                             SocietalDirect costsIndirect costs: lost productivity and lost time for patients and carers[@b14-ceor-3-117],[@b15-ceor-3-117]                                                                                     Most commonly used alternative[@b15-ceor-3-117]                                                                                                                                                                      Not specified                                                                                              No information found                                                                                                                                                                                                                                         Estimated average duration of useEstimated consumption (number of patients and utilization)Estimated cost of use per day[@b15-ceor-3-117]

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117],[@b114-ceor-3-117]                                                       No, but should be included if available[@b115-ceor-3-117],[@b172-ceor-3-117]                                                                                                     No information found                                                                                                                                                                                                                                                                                                    No information found                                                                                                                                                                                               No information found                                                                                                                                                                                                 No information found                                                                                       No information found                       Yes[@b115-ceor-3-117],[@b172-ceor-3-117]                                        No information found                                                                                                              Price in other European Union countriesReimbursement status in other European Union countriesEstimated cost of use per day[@b115-ceor-3-117],[@b172-ceor-3-117]

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Medicinal Products Reimbursement Committee of the Dutch Healthcare Insurance Board (recommendations)[@b116-ceor-3-117]               Yes for pharmaceuticals with added therapeutic value (Annex 1B), except for orphan pharmaceuticals with small budget impact or absence of active alternative[@b154-ceor-3-117]   Cost effectivenessCost utilityMethods must comply with Dutch Healthcare Insurance Board economic guidelines[@b36-ceor-3-117],[@b84-ceor-3-117],[@b173-ceor-3-117]                                                                                                                                                       SocietalDirect costs[@b154-ceor-3-117]Indirect costs may be included but must be reported separately[@b154-ceor-3-117]                                                                                             Most commonly used alternative ORMost relevant reimbursed alternative[@b84-ceor-3-117],[@b173-ceor-3-117]                                                                                                            One-way, multi-way, and probabilistic[@b35-ceor-3-117]                                                     No information found                       Yes[@b154-ceor-3-117]                                                           No information found                                                                                                              Anticipated substitution effectsPriceEstimated consumption (number of patients and utilization)[@b154-ceor-3-117]

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                    Yes[@b7-ceor-3-117]                                                                                                                                                              Cost effectivenessCost utilityMethods must comply with National Institute for Health and Clinical Excellence economic guidelines[@b13-ceor-3-117],[@b157-ceor-3-117]                                                                                                                                                    Payer[@b13-ceor-3-117],[@b157-ceor-3-117]Direct and indirect costs to National Health Service and Personal Social Services                                                                                         Most commonly used alternative ORBest practice alternative[@b13-ceor-3-117],[@b157-ceor-3-117]                                                                                                                       Probabilistic[@b157-ceor-3-117]                                                                            Yes[@b13-ceor-3-117],[@b157-ceor-3-117]    Yes[@b13-ceor-3-117],[@b157-ceor-3-117]                                         No information found                                                                                                              National Health Service resource implications[@b13-ceor-3-117],[@b157-ceor-3-117]

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b28-ceor-3-117]                                                              Yes[@b174-ceor-3-117]                                                                                                                                                            Any one of: Cost effectivenessCost utilityCost minimization/cost comparison; rationale for selection must be provided[@b28-ceor-3-117],[@b174-ceor-3-117]Methods must comply with economic guidelines[@b28-ceor-3-117],[@b174-ceor-3-117]                                                                               Societal[@b28-ceor-3-117]                                                                                                                                                                                          Most commonly used alternative[@b28-ceor-3-117]                                                                                                                                                                      Probabilistic[@b28-ceor-3-117]                                                                             Yes[@b28-ceor-3-117]                       Yes[@b28-ceor-3-117],[@b174-ceor-3-117]                                         No information found                                                                                                              National Health Service resource implications[@b28-ceor-3-117],[@b174-ceor-3-117]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of decision-making processes

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                                                              **Committee composition**                                                                                                                                                                                                                                                                                     **Steps in review/decision-making process**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **Use of cost-effectiveness threshold**                                                                                         **Timelines for review/decision**                                                                                                                                         **Appeals mechanisms**
  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                                                           20 voting members: 3 academics10 from sickness funds2 from physicians associations2 from economic chamber2 from federal chamber of labour1 from Austrian chamber of pharmacists                                                                                                                               Manufacturer submits application for reimbursement to Association of Austrian Social Security InstitutionsInternal staff (Department of Pharmaceutical Affairs) prepare evaluation of application (pharmacological and therapeutic) based on evidence presented in application, and assigns pharmaceutical to 1 of 6 categories of therapeutic value -- pharmaceuticals classified into categories 5 or 6 can request price above average European Union priceHealth economics team evaluates cost effectiveness of pharmaceutical relative to comparable alternativesPharmaceutical Evaluation Board deliberates over both evaluation reports and prepares reportPharmaceutical Evaluation Board sends report to manufacturer for commentPharmaceutical Evaluation Board prepares reimbursement recommendation, taking into account responses received from manufacturerDeputy director of Association of Austrian Social Security Institutions reviews recommendations and makes final decision[@b21-ceor-3-117],[@b56-ceor-3-117],[@b58-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No[@b21-ceor-3-117]                                                                                                             180 days (includes pricing and reimbursement decision)[@b58-ceor-3-117]                                                                                                   Decision may be appealed to Independent Pharmaceuticals Commission[@b58-ceor-3-117]

  Belgium           Minister of Social Affairs (decisions)Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]                                                                                                        31 members (23 voting including chair): 7 academics8 from sickness funds4 physicians3 from pharmacist associations\                                                                                                                                                                                           Manufacturer submits application for reimbursement to Secretariat of Drug Reimbursement Committee Includes incremental cost-effectiveness ratio (ICER) if Class I claim (added therapeutic value compared to existing alternatives) and simultaneously submits pricing dossier to Federal Public Service economyBrief overview report of product characteristics preparedStaff within Bureau of Drug Reimbursement Committee, supported by experts, prepare evaluation of pharmaceutical's safety, efficacy, effectiveness, applicability, and convenience based on evidence submitted by manufacturer; pricing commission simultaneously examines pricing dossier, determines maximum price, and notifies manufacturerDrug Reimbursement Committee discusses and approves evaluation reportDrug Reimbursement Committee sends report to manufacturerStaff prepare draft recommendations, taking into account evaluation report, price from manufacturer, and responses received from manufacturerDrug Reimbursement Committee discusses and approves (by 2/3 majority vote) draft recommendationsDrug Reimbursement Committee sends draft recommendations to manufacturer, who must reply within 10 days; manufacturer may request a hearingDrug Reimbursement Committee prepares final recommendations, taking into account responses received from manufacturerMinister receives recommendations, seeks advice from Minister of Budget and financial administration, and makes final decision[@b9-ceor-3-117],[@b17-ceor-3-117],[@b21-ceor-3-117],[@b62-ceor-3-117],[@b175-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No[@b62-ceor-3-117]                                                                                                             150 days (includes pricing and reimbursement)[@b21-ceor-3-117]                                                                                                            Decision may be appealed on procedural grounds onlyHeard by administrative court
                                                                                                                                                                                                                                                  Nonvoting: 2 from pharmaceutical industry1 from generic pharmaceutical industry4 from Ministries of Public Health, Social Affairs, and Economic Affairs, and FederalPublic Service Budget1 from National Institute for Health and Disability Insurance[@b62-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117],[@b170-ceor-3-117]                                                                                                                                              No information found                                                                                                                                                                                                                                                                                          Manufacturer submits application for reimbursement to State Institute for Drug ControlInternal staff (Department for Price and Reimbursement Regulation) consult with medical experts, health economists, and patient groups, and prepare evaluation report; assess safety, efficacy, and clinical use first, and then financial aspectsState Institute for Drug Control makes decision on price and level of reimbursement, based on evaluation report[@b176-ceor-3-117]--[@b180-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No[@b138-ceor-3-117]                                                                                                            75 days (includes pricing and reimbursement decision)                                                                                                                     Decision may be appealed to Ministry of Health

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                                                        Maximum of 7 members: Must include: 2 general practitioners1 representative of the regions[@b69-ceor-3-117]                                                                                                                                                                                                   Manufacturer submits application for reimbursement to Danish Medicines AgencyInternal staff, supported by external experts (if necessary) prepare evaluation report based on evidence submitted by manufacturer; clinical effect and safety profile compared to already reimbursed pharmaceutical and non-pharmaceutical products for same indicationDanish Medicines Agency simultaneously prepares price surveyHealth economics expert(s) evaluate(s) economic analysis, if submittedReimbursement Committee reviews evaluation report, price survey, and review of economic analysis and makes reimbursement recommendation to Danish Medicines AgencyIf negative, Danish Medicines Agency sends draft recommendations to manufacturerDanish Medicines Agency Board makes final decision [@b21-ceor-3-117],[@b68-ceor-3-117],[@b69-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No[@b68-ceor-3-117]                                                                                                             90 days after receipt of "adequate application"[@b38-ceor-3-117]                                                                                                          Decision may be appealed to Ministry of Health and Prevention[@b38-ceor-3-117],[@b68-ceor-3-117]

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                                                           No information found                                                                                                                                                                                                                                                                                          No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            No information found                                                                                                            No information found                                                                                                                                                      No information found

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]                                                   7 members of Pharmaceuticals Pricing Board: 2 from Ministry of Social Affairs and Health2 from Social Insurance Institution (Kela)1 from Ministry of Finance1 from National Agency for Medicines1 from National Research and Development Centre for Welfare and Health\                                       Manufacturer submits application for reimbursement to Pharmaceuticals Pricing Board secretariatInternal staff, with support from Expert Group, prepare evaluation report based on evidence submitted by manufacturerExpert Group reviews report and formulates opinionsPharmaceuticals Pricing Board Secretariat presents summary of report and opinions, along with written statement regarding the potential impact of the pharmaceutical on its budget provided by Kela, to Pharmaceuticals Pricing BoardPharmaceuticals Pricing Board formulates recommendationsIf negative, Pharmaceuticals Pricing Board sends recommendations to manufacturer, who may choose to lower price or provide additional evidencePharmaceuticals Pricing Board makes final decision[@b74-ceor-3-117],[@b122-ceor-3-117],[@b181-ceor-3-117],[@b182-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No[@b181-ceor-3-117]                                                                                                            180 days (includes pricing and reimbursement decision)[@b181-ceor-3-117]                                                                                                  Decision may be appealed to Supreme Court[@b181-ceor-3-117]
                                                                                                                                                                                                                                                  7 members of Expert Group: Includes individuals with medical, pharmacological, health economics, and social insurance expertise[@b75-ceor-3-117],[@b181-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                                                                 Transparency Committee within French National Authority for Health: 20 voting members (includes chair): 4 from "public institutions"3 from main health insurance fund1 from pharmaceutical industry12 with medical and pharmacological expertise[@b78-ceor-3-117],[@b184-ceor-3-117]\                         *Single technology appraisals*Manufacturer submits application for reimbursement to French National Authority for Health secretariatInternal staff prepare evaluation report based on evidence submitted by manufacturer (focuses on clinical effectiveness, target population, conditions of use, and already reimbursed technologies)External clinical and methodological experts review evaluation reportCommission d'Evaluation des Medicaments reviews evaluation report and expert opinions to appraise the "medical benefit" of the pharmaceutical (on a 5 point scale; I -- major to V -- insufficient to justify reimbursement)Minister makes final decision on the medical benefit level/scoreCommission d'Evaluation des Medicaments then performs comparative assessment of pharmaceutical with already reimbursed alternatives to appraise the "improvement in medical benefit" (on a 6 point scale; 1 -- major innovation to VI -- negative opinion regarding inclusion on benefit list)Transparency Commission considers advice received from Commission d'Evaluation des Medicaments and assigns an "improvement in medical benefit" classification to the pharmaceuticalOnce positive reimbursement recommendation is received, the Comite Economique des produits de Sante = negotiates price with manufacturer and the Union Nationale des Caisses d'Assurance Maladie fixes the reimbursement rateMinister for Health and Social Security makes final decision on reimbursement level and price[@b16-ceor-3-117],[@b20-ceor-3-117]--[@b23-ceor-3-117]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      No[@b20-ceor-3-117]                                                                                                             90 days for inpatient pharmaceuticals (includes pricing and reimbursement)180 days for outpatient pharmaceuticals (includes pricing and reimbursement)[@b20-ceor-3-117]   May appeal recommendation to French National Authority for Health, requesting a hearing or providing written commentsOnce decision has been made, may appeal to administrative court[@b20-ceor-3-117]
                                                                                                                                                                                                                                                  7 Specialist subcommittees of clinical experts                                                                                                                                                                                                                                                                Multiple technology appraisals French National Authority for Health approves technology topic for multiple technology appraisalsFrench National Authority for Health conducts consultations with relevant stakeholders and the Interdisciplinary Economic Evaluation and Public Health Committee to define scope and protocol for multiple technology appraisalsInternal staff and/or independent academic group prepares assessment report (includes clinical review and economic analysis)Interdisciplinary Economic Evaluation and Public Health Committee and external experts review assessment reportStakeholders receive assessment report for commentStakeholders also consulted through working group meetingsAppropriate health technology assessment specialist subcommittee appraises report and comments and formulates recommendationsFrench National Authority for Health Board reviews and approves recommendations[@b21-ceor-3-117],[@b185-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117]                                                                                    13 members including representatives from: Associations of physicians, dentists, and physiotherapistsHospital associationsSickness fundsPatient organizations (nonvoting)[@b18-ceor-3-117],[@b19-ceor-3-117]                                                                                                  Federal Joint Committee makes decision to assess technology and notifies Institute for Quality and Efficiency in Health CareInstitute for Quality and Efficiency in Health Care appoints internal staff to manage and/or conduct assessmentInstitute for Quality and Efficiency in Health Care carries out consultations with external clinical experts and patient/carer organizations to define assessment scope and protocolInstitute for Quality and Efficiency in Health Care posts draft scope and protocol on website for public commentInternal staff, supported by external experts, prepare assessment, first considering clinical benefit or innovativeness (ie, is the first active ingredient or offers therapeutic improvement); if deemed noninnovative, technology is assigned to 1 of 3 groups (1: identical active ingredient; 2: therapeutically comparable and one active ingredient; 3: therapeutically comparable and two active ingredients); technologies with similar efficacy/effectiveness must demonstrate comparable efficiency through findings from efficiency frontier analysis[@b119-ceor-3-117]; if deemed innovative (ie, offers added therapeutic value over already reimbursed alternatives), "cost-benefit" analysis is performed to set maximum reimbursable amount; if technology treats life-threatening condition for which there are no alternatives, cost must not be considered[@b18-ceor-3-117],[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care steering committee reviews draft report and recommendations for quality assuranceInstitute for Quality and Efficiency in Health Care posts draft report and recommendations on website for public commentStaff prepare final report, incorporating comments received and recommendations, and submit it to the Institute for Quality and Efficiency in Health Care steering committee for final quality assurance review and then to the Board for final approvalBoard sends recommendations to Federal Joint Committee, who makes final decision[@b19-ceor-3-117],[@b24-ceor-3-117],[@b124-ceor-3-117],[@b144-ceor-3-117]   No[@b18-ceor-3-117]                                                                                                             No information found                                                                                                                                                      May not appeal recommendationsDecision may be appealed to administrative court[@b18-ceor-3-117]

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117],[@b86-ceor-3-117]                                                                                                       7 members including representatives from: Ministry of HealthMinistry of FinanceMinistry of Employment and Social ProtectionMerchant Marine[@b85-ceor-3-117]                                                                                                                                                   Manufacturer submits application for reimbursement to Transparency Committee in the Reimbursement and Medicinal ProductsTransparency Committee in the Reimbursement and Medicinal Products recommends classification of pharmaceutical into pre-existing therapeutic category based on "therapeutic and pharmacoeconomic effectiveness"Transparency Committee in the Reimbursement and Medicinal Products sends classification recommendation to Ministry of Health and Social Security for approvalPrice set taking into account products already included in assigned category or average of the 3 lowest European prices[@b186-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No information found                                                                                                            90 days (includes pricing and reimbursement decision)[@b186-ceor-3-117]                                                                                                   No information found

  Hungary           Ministers of Health and FinanceNational Health Insurance Fund Administration Technology Appraisal Committee (recommendations)[@b88-ceor-3-117],[@b89-ceor-3-117]                                                              Technology Appraisal Committee: includes members delegated by stakeholder groups[@b102-ceor-3-117]                                                                                                                                                                                                            Manufacturer submits application for reimbursement to Transparency Secretariat of National Health Insurance Fund Administration (pharmaceutical division)Transparency Secretariat registers and checks application for completeness and then determines whether application should undergo simplified procedure or normal procedure; normal procedure applies to new agents, indications, routes of administration, and combinationsNational Health Insurance Fund Administration Department of Pharmaceuticals prepares a preliminary evaluationIf application is assigned to normal procedure, Transparency Secretariat transfers it to Technology Assessment Office of the National Institute for Strategic Health ResearchAssessment Office prepares assessment report comprising a systematic review of clinical evidence and economic analysisTechnology Appraisal Committee deliberates over report, preliminary evaluation of pharmaceutical department, and advice from professional colleges, and formulates a recommendationDirector of pharmaceutical division approves recommendation and forwards it to the Ministers of Health and Finance[@b90-ceor-3-117],[@b102-ceor-3-117],[@b187-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                No information found                                                                                                            No information found                                                                                                                                                      Decision may be appealed to Appeals Committee Includes representatives from: Ministry of HealthMinistry of FinanceMinistry of EconomyNational Institute of PharmacyPrime Minister's office[@b90-ceor-3-117]

  Ireland           Products Committee of Corporate Pharmaceuticals Unit of Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                               No information found                                                                                                                                                                                                                                                                                          1\. Products Committee of Health Service Executive selects technology for assessment OR manufacturer submits application for reimbursement to Health Service Executive2a. If Products Committee selects technology, Health Service Executive notifies manufacturer of referral to National Centre for Pharmacoeconomics2b. If manufacturer submits application, staff prepare preliminary evaluation report based on evidence from manufacturer3a. Staff within National Centre for Pharmacoeconomics appointed to comprise review group3b. Products Committee reviews evaluation report and decides whether to refer technology to National Centre for Pharmacoeconomics for formal pharmacoeconomic evaluation or recommend reimbursement4a. Review group meets with manufacturer to determine scope and requirements for evaluation4b. If referred, National Centre for Pharmacoeconomics conducts pharmacoeconomic evaluation5a. Manufacturer prepares pharmacoeconomic submission, which includes cost-effectiveness and budget impact analyses5b. National Centre for Pharmacoeconomics sends pharmacoeconomic evaluation to manufacturer for comment6a. Review group prepares evaluation report based on manufacturer's submission6b. National Centre for Pharmacoeconomics prepares final pharmacoeconomic evaluation, incorporating manufacturer's comments7a. National Centre for Pharmacoeconomics sends report to manufacturer for comment7b. National Centre for Pharmacoeconomics sends evaluation to Products Committee, who makes reimbursement decision8a. Review group prepares final evaluation report, incorporating manufacturer's comments9a. National Centre for Pharmacoeconomics sends report to Products Committee, who makes reimbursement decision[@b91-ceor-3-117],[@b93-ceor-3-117],[@b125-ceor-3-117],[@b147-ceor-3-117]                                                                                                                                                                                                                                                                                         No fixed threshold, but €45,000/QALY used as a guide[@b91-ceor-3-117],[@b125-ceor-3-117],[@b165-ceor-3-117]                     90 days (for reimbursement decision)[@b93-ceor-3-117]                                                                                                                     Decision may be appealed to designated expert committee[@b91-ceor-3-117]

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]                                           Technical Scientific Committee: Includes 17 members: Health care providersPharmacistsPharmacologists Pricing and Reimbursement Committee: Includes 12 members:AcademicsHealth care providersAdministrators responsible for managing pharmaceuticalservices[@b95-ceor-3-117]                                   Manufacturer submits application for reimbursement to Italian Medicines AgencyTechnical Scientific Committee reviews submission and formulates advice on clinical value, assigning it to one of three reimbursement classes: A -- fully reimbursable -- essential products and those intended for chronic diseases; H -- Fully reimbursable in hospitals; and C -- non-reimbursable. Pharmaceuticals in classes A and H are further assigned to one of three classes: I -- treatments for serious diseases; II -- treatments to reduce or eliminate risk of serious diseases; and III -- treatments for non-serious diseasesTechnical Scientific Committee then assesses the degree of innovation offered by the technology, considering 2 factors: 1) availability of existing treatments and 2) extent of therapeutic benefit; scores on each factor are combined to determine if pharmaceutical represents "important," "moderate," or "modest therapeutic innovation"Submission and Technical Scientific Committee evaluation are sent to Pricing and Reimbursement CommitteePricing and Reimbursement Committee reviews advice and contacts manufacturer to negotiate reimbursement status and pricePricing and Reimbursement Committee submits report containing negotiation outcomes to Technical Scientific Committee, who makes final decision [@b26-ceor-3-117],[@b27-ceor-3-117],[@b126-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No[@b126-ceor-3-117]                                                                                                            180 days (includes pricing and reimbursement decision)[@b188-ceor-3-117]                                                                                                  No information found

  Norway            Norwegian Medicines Agency (recommendations/decisions)[@b34-ceor-3-117],[@b98-ceor-3-117]Ministry of Health and Care Services (recommendations/decisions)Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]   No information found                                                                                                                                                                                                                                                                                          Process depends on anticipated budget impact of pharmaceutical: If \<5 million Krone/year: Manufacturer submits application for reimbursement to Norwegian Medicines AgencyNorwegian Medicines Agency Department of Pharmacoeconomics staff prepare evaluation report based on evidence submitted by manufacturerNorwegian Medicines Agency reviews evaluation report and makes reimbursement decision If \> 5 million Krone/year:Manufacturer submits application for reimbursement to Norwegian Medicines AgencyNorwegian Medicines Agency Department of Pharmacoeconomics staff prepare evaluation report based on evidence submitted by manufacturerNorwegian Medicines Agency reviews evaluation report and consults with National Advisory Committee for Drug ReimbursementNorwegian Medicines Agency sends evaluation report to Ministry of Health and Care ServicesMinistry consults with National Council for Health Care Priorities to determine whether pharmaceutical would be viewed as" money well spent"Ministry formulates recommendation; if positive, it is sent to Parliament for approval[@b34-ceor-3-117],[@b98-ceor-3-117],[@b189-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             No[@b34-ceor-3-117]                                                                                                             180 days (includes pricing and reimbursement decision)[@b34-ceor-3-117]                                                                                                   No information found

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117]Agency for Health Technology Assessment Consultative Council and Drug Management Team (recommendations)[@b99-ceor-3-117]                                                       Consultative Council: 12 voting members including representatives from: Ministry of Health (7)Polish Chamber of Physicians (1)Chief Pharmaceutical Council (1)Supreme Council of Nurses and MidwivesNational Health Fund[@b127-ceor-3-117]\                                                                   Manufacturer submits application for reimbursement to Ministry of HealthMinistry of Health sends application to the Agency for Health Technology AssessmentAgency for Health Technology Assessment staff prepare evaluation report based on evidence from the submission and information received from invited expertsAgency for Health Technology Assessment Consultative Council meets to review report, hear from experts, and formulate recommendationsDirector of Agency for Health Technology Assessment issues reimbursement recommendation to Minister of HealthDrug Management Team within Ministry of Health negotiates maximum reimbursement priceMinistry of Health makes final decision on reimbursement and price[@b100-ceor-3-117],[@b127-ceor-3-117],[@b190-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No information found                                                                                                            180 days (includes pricing and reimbursement decision)[@b100-ceor-3-117]                                                                                                  None[@b127-ceor-3-117]
                                                                                                                                                                                                                                                  Drug Management Team: Includes representatives of: Minister of FinanceMinister of Economy and LabourMinister of Social PolicyNational Health Fund[@b99-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b44-ceor-3-117]                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                          Manufacturer submits application for reimbursement to INFARMED following approval of maximum price by Directorate General of Economic ActivitiesExternal experts prepare evaluation report based on evidence submitted by manufacturer (includes pharmacotherapeutic and pharmacoeconomic information demonstrating added therapeutic value and proposed reimbursement price) and assigns "grade" of innovation and added therapeutic value (compared to already reimbursed alternatives)Economists analyze pharmacotherapeutic information from manufacturer to determine "economic advantage"; if pharmaceutical offers added therapeutic value or treats a condition for which there are no alternative therapies, economic advantage should be demonstrated through formalUsing findings from both reports, INFARMED formulates reimbursement recommendationIf negative, INFARMED contacts manufacturer, who may present additional informationINFARMED submits recommendations to Minister, who makes final decision[@b36-ceor-3-117],[@b101-ceor-3-117],[@b191-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                No information found                                                                                                            90 days (includes pricing and reimbursement decision)[@b36-ceor-3-117]                                                                                                    Decision may be appealed to administrative court[@b36-ceor-3-117]

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                                                                  No information found                                                                                                                                                                                                                                                                                          Manufacturer submits application for reimbursement to Scottish Medicines ConsortiumInternal staff ("assessment team"), supported by clinical and economic experts, prepare evaluation report based on evidence submitted by manufacturerNew Drugs Committee reviews report and prepares draft recommendations for the Scottish Medicines ConsortiumNew Drugs Committee also sends draft recommendations to manufacturer for commentManufacturer sends comments to Scottish Medicines Consortium, which also considers submissions received from patient interest groupsScottish Medicines Consortium formulates final recommendations and forwards them to the National Health Service Boards, Area Drug and Therapeutics Committees, manufacturer, and competitor(s)[@b30-ceor-3-117],[@b128-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No fixed threshold, but range of £20,000--£30,000/QALY used as a guide[@b30-ceor-3-117]                                         No information found                                                                                                                                                      Decisions may be appealed on process-related and scientific groundsFor process-related appeals: Manufacturer contacts Scottish Medicines Consortium secretariat, Chair, or New Drugs Committee to resolve issues through discussionFor scientific disputes: May resubmit or convene independent panel appointed by Scottish Medicines Consortium

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b107-ceor-3-117]                                                                                           Reimbursement Committee:\                                                                                                                                                                                                                                                                                     Manufacturer submits application for reimbursement, including proposed maximum retail price, to Ministry of HealthStaff evaluate pharmaceutical using evidence from manufacturer to determine where its ICER lies in the accepted ICER threshold rangeOne of 22 specialist working groups then evaluates the pharmaceutical according to its anatomic and therapeutic classificationA separate working group evaluates pharmacoeconomic dataEvaluations from both working groups are forwarded to the Reimbursement CommitteeThe Reimbursement Committee reviews the reports and formulates a reimbursement decision[@b102-ceor-3-117],[@b106-ceor-3-117],[@b107-ceor-3-117],[@b131-ceor-3-117],[@b169-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              No fixed threshold, but range of €20,000--€26,500/QALY used as a guide[@b105-ceor-3-117]                                        No information found                                                                                                                                                      Decision may be appealed to Ministry
                                                                                                                                                                                                                                                  Includes 11 members representing: Ministry of Health (3)Slovakian medical chamber (3)Health insurance funds (5)[@b101-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                                                                  Inter-Ministerial Pricing Commission: Includes representatives from: Ministry of HealthMinistry of EconomyMinistry of Industry[@b132-ceor-3-117]                                                                                                                                                              Ministry of Health initiates reimbursement decision-making process upon receipt of notice of market approval for new pharmaceuticalMinistry of Health invites manufacturer to provide all relevant information to Inter-Ministerial Pricing CommissionInternal staff of Ministry of Health prepare evaluation reportInter-Ministerial Pricing Commission reviews report and makes reimbursement and pricing decision[@b108-ceor-3-117],[@b132-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No[@b132-ceor-3-117]                                                                                                            180 days (includes pricing and reimbursement decision)[@b132-ceor-3-117]                                                                                                  No information found

  Sweden            Dental and Pharmaceutical Benefits Board Expert Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117]                                                                                                                         Expert Board: Includes 11 members and a chair: Pharmacologist (1)Health economists (4)Patient representatives (2)Health care providers (3)[@b15-ceor-3-117],[@b109-ceor-3-117]                                                                                                                                Manufacturer submits application for reimbursementInternal staff (executive officer, health economist, and legal expert) review submission to determine if application contains sufficient evidenceDental and Pharmaceutical Benefits Board sends copy of application to Pharmaceutical Benefits Group for County Councils for reviewInternal staff prepare evaluation report and draft recommendations in the form of a "memorandum"Dental and Pharmaceutical Benefits Board sends copy of memorandum to manufacturer for reviewManufacturer may request a meeting with the Board, during which it can present case, dispute arguments which form the basis of recommendations, and refute factual errorsMeeting of Expert Board held -- memorandum, manufacturer's comments, and any feedback received from the Pharmaceutical Benefits Group are reviewed; external experts may be invited to participate in deliberations;Expert Board makes final reimbursement decision[@b33-ceor-3-117],[@b192-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No fixed threshold, but €45,000/QALY used as a guide[@b35-ceor-3-117]                                                           180 days (includes pricing and reimbursement decision)[@b192-ceor-3-117]                                                                                                  Decision may be appealed on procedurals grounds only[@b15-ceor-3-117],[@b33-ceor-3-117],[@b192-ceor-3-117]Board may reconsider decision before appeal is heard by administrative court[@b192-ceor-3-117]

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117],[@b114-ceor-3-117]                                                                                               Federal Drug Commission: Includes 25 voting members representing: Academics (4)Physicians (3)Pharmacists (3)Health insurers (5)Hospitals (1)Patient organizations (2)Manufacturers (2)Federal Office of Social Insurance (1)Cantons (1)Swissmedic (1)Army pharmacy (1)[@b113-ceor-3-117],[@b114-ceor-3-117]   Manufacturer submits application for reimbursementFederal Drug Commission reviews application and makes a classification recommendation: pharmaceutical may be classified into one of five categories of relative effectiveness: 1 -- Therapeutic breakthrough; 2 -- Therapeutic progress; 3 -- Saving compared to other drugs; 4 -- No therapeutic progress and no savings; and 5 -- Not appropriate for the social health insuranceFederal Office of Public Health makes final decision, based on Federal Drug Commission's recommendation, assessment by Swiss Agency for Therapeutic Products for market authorization and internal and external price referencingIf Federal Office of Public Health plans to make a negative decision, the manufacturer is informed prior to issuing the final decision; manufacturer may apply for re-evaluation on the basis of price adjustments or availability of additional data[@b114-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No information found                                                                                                            No information found                                                                                                                                                      Decision may be appealed to Federal Office of Public Health[@b114-ceor-3-117]

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Dutch Healthcare Insurance Board Committee (CHF) (recommendations)[@b26-ceor-3-117]                                                                                          Committee of the Dutch Healthcare Insurance Board: Includes: A maximum of 24 members with expertise in various medical disciplines, health sciences and economics2--3 nonvoting members from the Ministry[@b21-ceor-3-117],[@b117-ceor-3-117]\                                                                For outpatient pharmaceuticals: Manufacturer submits application for reimbursement to Minister of HealthInternal staff prepare evaluation, which includes 4 draft reports (summary, pharmacotherapeutic, pharmacoeconomic, and budget impact assessments based on evidence from manufacturer, as well as independently conducted literature review); if deemed necessary, staff may consult with manufacturer, external experts, and stakeholdersCHF reviews report and consults with manufacturer and other stakeholdersStaff revise report, incorporating results of CHF deliberations and comments from manufacturer and other stakeholdersDutch Healthcare Insurance Board sends revised report to manufacturer and stakeholders for commentCHF meets to discuss revised report and comments received and prepare final adviceDutch Healthcare Insurance Board board of directors receives final report, which is also sent to manufacturer and stakeholders appointed by Dutch Healthcare Insurance Board for commentDutch Healthcare Insurance Board board of directors meet to discuss final report and comments received and formulate recommendations; may consult with the Appraisal CommitteeAlternatively, Steps 7 and 8 may be skipped, with the Board chair drafting a recommendationDutch Healthcare Insurance Board sends final recommendations to the Minister of Healthcare, Welfare, and SportMinister makes final reimbursement decision, which includes classifying the pharmaceutical into one of three categories: Annex 1A -- Therapeutic equivalent value;Annex 1B -- Therapeutic added value; andAnnex 2 -- Conditional reimbursement\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                No fixed threshold, but €20,000/QALY used as a guide [@b31-ceor-3-117]                                                          90 days for outpatient pharmaceuticals60 days for inpatient pharmaceutical[@b21-ceor-3-117]                                                                               Decision may be appealed on procedural grounds onlyAppeal is heard by administrative court[@b21-ceor-3-117]
                                                                                                                                                                                                                                                  Includes: 3 Dutch Healthcare Insurance Board board of directors6 members with health and social security insurance expertise[@b21-ceor-3-117]                                                                                                                                                                 For high-cost inpatient pharmaceuticals: Dutch Federation of University Hospitals, Dutch Hospitals Association, Medical Specialists Association, and Dutch Health Insurance Organization may submit reimbursement application (in the form of additional funding) for high cost inpatient pharmaceuticalsDutch Healthcare Insurance Board prepares evaluation report, which includes evidence on therapeutic value, projected budget impact, and plan for collecting pharmacoeconomic information in daily practice, and formulates recommendations (process similar to that described above)Dutch Healthcare Insurance Board sends final report and recommendations to the Dutch Healthcare AuthorityDutch Healthcare Authority formulates recommendation on whether pharmaceutical should be provisionally added to the Expensive Drug ListMinister of Health, Welfare, and Sport makes final decision[@b21-ceor-3-117],[@b31-ceor-3-117],[@b49-ceor-3-117],[@b116-ceor-3-117],[@b117-ceor-3-117],[@b193-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                                                            Includes: Academics (eg, health economists)Health care providers in National Health ServiceRepresentatives from patient and carer organizationsManufacturers[@b29-ceor-3-117]                                                                                                                                 Single technology appraisal Topics selection panel selects technology for reviewNational Institute for Health and Clinical Excellence invites stakeholders (ie, consultees and commentators (cannot make a submission or appeal recommendation)) to participateNonmanufacturer consultees invited to nominate clinical and/or patient experts to take part in Technology Appraisals Committee meetingsManufacturer completes evidence submission (assessment)Independent academic group commissioned to review submission, along with information received from consultees and nominated experts, and prepare evaluation reportTechnology Appraisals Committee meets to review evaluation report and hear from nominated clinical and patient expertsTechnology Appraisals Committee formulates draft recommendations, which are presented in appraisal consultation documentAppraisal consultation document made available to stakeholders for commentTechnology Appraisals Committee meets to consider comments and formulate final recommendations (final appraisal determination)Technology Appraisals Committee submits final recommendations to Guidance ExecutiveGuidance Executive makes final reimbursement decision[@b29-ceor-3-117],[@b194-ceor-3-117],[@b195-ceor-3-117]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           No fixed threshold, but range of £20,000--£30,000/QALY used as a guide[@b37-ceor-3-117],[@b196-ceor-3-117],[@b197-ceor-3-117]   Single technology appraisal approximately 39 weeks[@b29-ceor-3-117]                                                                                                       Final recommendations may be appealed on procedural grounds onlyAppeals may only be initiated by consultees identified at the beginning of the assessment and who are not representing National Health Service trusts or local boardsAppeal is heard by Appeals Panel appointed by National Institute for Health and Clinical Excellence board[@b39-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Multiple technology appraisal\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Same as single technology appraisal process except:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1) Formal scoping process to develop review protocol is required; 2) Independent academic group conducts assessment (rather than the manufacturer); 3) Independent academic group attends Technology Appraisals Committee meetings[@b13-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group New Medicines Group (recommendations)[@b120-ceor-3-117]                                                                                 Includes: PhysiciansPharmacistsPharmacologistsHealth economistNursePatient representativeRepresentative from pharmaceutical industry association[@b28-ceor-3-117]                                                                                                                                             Manufacturer submits application for reimbursement ("Form A") to All Wales Medicines Strategy GroupAll Wales Medicines Strategy Group determines whether application requires full appraisal; if yes, manufacturer must submit "Form B"All Wales Medicines Strategy Group identifies and invites clinical experts and patient organizations to submit written statementsInternal staff prepare evaluation report, which includes Form A, Form B, and additional relevant informationReport sent to manufacturer for commentAll Wales Medicines Strategy Group New Medicines Group meets to review evaluation report and comments received and formulate draft recommendationsStaff prepare final report and draft recommendations (ie, preliminary appraisal), which is sent to manufacturer and posted on websiteNew Medicines Group meets to deliberate over final report, recommendations, and manufacturer's responseNew Medicines Group formulates final recommendation, which is included in final appraisalMinister makes reimbursement decision, based on final appraisal from New Medicines Group[@b28-ceor-3-117],[@b120-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No fixed threshold, £20,000/QALY used as a guide[@b28-ceor-3-117]                                                               No information found                                                                                                                                                      Decisions may be appealed on process-related and scientific groundsFor process-related appeals: Appeals submitted to Welsh Medicines Partnership, who discusses case with All Wales Medicines Strategy Group Chair and senior staffFor scientific disputes: Independent review process initiated[@b198-ceor-3-117]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of key factors considered during committee deliberations

  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                      **Clinical need**                          **Clinical benefit/value[\*](#tfn2-ceor-3-117){ref-type="table-fn"}**   **Cost-benefit ratio (cost-effectiveness; efficiency; "value for money")[^†^](#tfn3-ceor-3-117){ref-type="table-fn"}**   **Impact on health resources/affordability (budget impact)**   **Innovativeness**                                                  **Other**                                                                                                                                                                                                                                                                              
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                   Yes[@b55-ceor-3-117]                       Yes[@b58-ceor-3-117]                                                    Not specified                                                                                                            Not specified                                                  Yes[@b55-ceor-3-117]                                                Not specified                            Not specified                            Yes ("pharmacoeconomic evidence")[@b58-ceor-3-117]                  Yes[@b55-ceor-3-117]                                                                  Yes[@b50-ceor-3-117]                       Price in other European Union countries[@b58-ceor-3-117]
  Belgium           Ministry of Health and Social Affairs (decisions)Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]                                                     Yes[@b11-ceor-3-117],[@b17-ceor-3-117]     Yes[@b21-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b9-ceor-3-117]                                            Yes (across patient subgroups)[@b9-ceor-3-117]                      Yes[@b9-ceor-3-117]                      Yes[@b11-ceor-3-117],[@b17-ceor-3-117]   Yes[@b11-ceor-3-117],[@b17-ceor-3-117]                              Yes[@b11-ceor-3-117],[@b17-ceor-3-117]                                                Yes[@b35-ceor-3-117]                       Feasibility of implementation[@b11-ceor-3-117],[@b17-ceor-3-117]Market price[@b11-ceor-3-117],[@b17-ceor-3-117]Social needs[@b11-ceor-3-117],[@b17-ceor-3-117],[@b21-ceor-3-117]
  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117],[@b176-ceor-3-117]                                                                                                      Yes[@b84-ceor-3-117]                       Yes[@b84-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b84-ceor-3-117]                                           Yes[@b84-ceor-3-117]                                                Not specified                            Yes[@b66-ceor-3-117]                     Yes[@b84-ceor-3-117]                                                Yes[@b84-ceor-3-117]                                                                  Not specified                              Clinical practice guidelines[@b138-ceor-3-117]Public interest[@b35-ceor-3-117]
  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                Not specified                              Not specified                                                           Not specified                                                                                                            Yes[@b21-ceor-3-117],[@b68-ceor-3-117]                         Yes (across patient subgroups)[@b21-ceor-3-117],[@b68-ceor-3-117]   Yes[@b21-ceor-3-117],[@b68-ceor-3-117]   Not specified                            Yes[@b21-ceor-3-117],[@b68-ceor-3-117]                              Not specified                                                                         Not specified                              Reasonableness of price relative to therapeutic value[@b21-ceor-3-117],[@b68-ceor-3-117]
  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                   Yes[@b84-ceor-3-117]                       Yes[@b84-ceor-3-117]                                                    Not specified                                                                                                            Not specified                                                  Yes[@b84-ceor-3-117]                                                Not specified                            Not specified                            Yes[@b84-ceor-3-117]                                                Yes[@b84-ceor-3-117]                                                                  Not specified                              "Cost efficiency"[^§^](#tfn4-ceor-3-117){ref-type="table-fn"}[@b140-ceor-3-117]
  Finland           Pharmaceuticals Pricing Board (decisions)[@b74-ceor-3-117],[@b76-ceor-3-117],[@b77-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]           Yes[@b181-ceor-3-117]                      Yes[@b181-ceor-3-117]                                                   Not specified                                                                                                            Not specified                                                  Yes (across patient subgroups)[@b181-ceor-3-117]                    Not specified                            Not specified                            Yes[@b181-ceor-3-117]                                               Yes[@b181-ceor-3-117]                                                                 Not specified                              Research and development[@b35-ceor-3-117]Level of uncertainty in supporting evidence[@b181-ceor-3-117]Price in other European Union countries[@b181-ceor-3-117]Market forecast and share[@b75-ceor-3-117]Daily cost of treatment per day[@b75-ceor-3-117]
  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                         Yes[@b35-ceor-3-117]                       Yes[@b35-ceor-3-117]                                                    Yes[@b35-ceor-3-117]                                                                                                     Yes[@b80-ceor-3-117]                                           Yes[@b35-ceor-3-117]                                                Yes[@b80-ceor-3-117]                     Yes[@b80-ceor-3-117]                     Not specified                                                       Yes[@b80-ceor-3-117]                                                                  Yes[@b35-ceor-3-117]                       Public health impact[@b16-ceor-3-117],[@b35-ceor-3-117]Costs relative to current treatment[@b199-ceor-3-117]
  Germany           Federal Joint Committee (decisions)[@b24-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117],[@b24-ceor-3-117]                          Yes[@b19-ceor-3-117]                       Yes[@b19-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b19-ceor-3-117]                                           Yes[@b19-ceor-3-117]                                                Not specified                            Not specified                            Yes[^‡^](#tfn5-ceor-3-117){ref-type="table-fn"}[@b119-ceor-3-117]   Yes[@b113-ceor-3-117]                                                                 Yes[@b19-ceor-3-117]                       
  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117]                                                                                 Yes[@b186-ceor-3-117]                      Yes[@b186-ceor-3-117]                                                   Not specified                                                                                                            Yes[@b186-ceor-3-117]                                          Yes[@b186-ceor-3-117]                                               Not specified                            Not specified                            Yes ("pharmacoeconomic effectiveness")[@b186-ceor-3-117]            Not specified                                                                         Not specified                              Daily cost of treatment[@b186-ceor-3-117]Reimbursement status in other European Union countries[@b186-ceor-3-117]
  Hungary           Ministers of Health and FinanceNational Health Insurance Fund Administration (recommendations)[@b88-ceor-3-117]                                                                       Yes[@b186-ceor-3-117]                      Yes[@b84-ceor-3-117]                                                    Not specified                                                                                                            Not specified                                                  Yes[@b84-ceor-3-117]                                                Not specified                            Not specified                            Yes[@b186-ceor-3-117]                                               Yes[@b84-ceor-3-117]                                                                  Not specified                              Equity[@b26-ceor-3-117]
  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117],[@b147-ceor-3-117]                                                                                            Yes[@b125-ceor-3-117],[@b165-ceor-3-117]   Yes[@b125-ceor-3-117],[@b165-ceor-3-117]                                Not specified                                                                                                            Not specified                                                  Yes[@b125-ceor-3-117],[@b165-ceor-3-117]                            Not specified                            Not specified                            Yes[@b125-ceor-3-117],[@b165-ceor-3-117]                            Yes[@b125-ceor-3-117],[@b165-ceor-3-117]                                              Yes[@b125-ceor-3-117],[@b165-ceor-3-117]   Level of uncertainty in supporting evidence[@b125-ceor-3-117]Wider societal costs and benefits[@b165-ceor-3-117]
  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]   Yes[@b27-ceor-3-117]                       Yes[@b27-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b96-ceor-3-117]                                           Yes (across patient subgroups)[@b27-ceor-3-117]                     Not specified                            Yes[@b27-ceor-3-117]                     Yes[@b27-ceor-3-117]                                                Yes[@b27-ceor-3-117]                                                                  Yes[@b20-ceor-3-117]                       Daily cost of treatment[@b27-ceor-3-117]"Special medical needs"[@b96-ceor-3-117]Price in other European Union countries[@b200-ceor-3-117]Market forecast and share[@b96-ceor-3-117]
  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]                                                             Yes[@b34-ceor-3-117]                       Not specified                                                           Not specified                                                                                                            Yes[@b149-ceor-3-117]                                          Yes (across patient subgroups)[@b34-ceor-3-117]                     Not specified                            Not specified                            Yes[@b34-ceor-3-117]                                                Yes[@b34-ceor-3-117]                                                                  Not specified                              Equity[@b35-ceor-3-117]"Solidarity"[@b34-ceor-3-117]"Rationality"[@b34-ceor-3-117]
  Poland            Ministry of Health (decisions)[@b99-ceor-3-117]                                                                                                                                       Yes[@b84-ceor-3-117]                       Not specified                                                           Not specified                                                                                                            Yes[@b84-ceor-3-117]                                           Yes[@b84-ceor-3-117]                                                Not specified                            Not specified                            Yes[@b84-ceor-3-117]                                                Yes[@b84-ceor-3-117]                                                                  Not specified                              
  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b36-ceor-3-117],[@b44-ceor-3-117]                                                                                           Yes[@b36-ceor-3-117]                       Yes[@b36-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b36-ceor-3-117]                                           Yes[@b36-ceor-3-117]                                                Not specified                            Not specified                            Yes[@b36-ceor-3-117]                                                Not specified                                                                         Not specified                              Equity[@b36-ceor-3-117]"Universality"[@b36-ceor-3-117]"Accessibility"[@b36-ceor-3-117]
  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                          Yes[@b104-ceor-3-117]                      Yes[@b30-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b104-ceor-3-117]                                          Yes[@b104-ceor-3-117]                                               Not specified                            Not specified                            Yes[@b104-ceor-3-117]                                               Yes[@b104-ceor-3-117]                                                                 Yes[@b30-ceor-3-117]                       Whether pharmaceutical reverses rather than stabilizes condition or bridges a gap to curative therapy[@b104-ceor-3-117]Level of uncertainty in supporting evidence[@b30-ceor-3-117]Wider societal costs and benefits[@b30-ceor-3-117]
  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b107-ceor-3-117],[@b169-ceor-3-117]                                Yes[@b106-ceor-3-117]                      Yes[@b84-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b106-ceor-3-117]                                          Yes[@b106-ceor-3-117]                                               Yes[@b106-ceor-3-117]                    Yes[@b106-ceor-3-117]                    Yes[@b84-ceor-3-117],[@b105-ceor-3-117]                             Yes[@b84-ceor-3-117],[@b106-ceor-3-117]                                               Not specified                              Price of other pharmaceuticals within reference category[@b106-ceor-3-117]
  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                          Yes[@b132-ceor-3-117]                      Yes[@b132-ceor-3-117]                                                   Not specified                                                                                                            Yes[@b10-ceor-3-117]                                           Yes (across patient subgroups)[@b132-ceor-3-117]                    Not specified                            Not specified                            Not specified                                                       Yes[@b132-ceor-3-117]                                                                 Yes[@b108-ceor-3-117]                      "Social utility"[@b132-ceor-3-117]Rationalization of public expenditures on pharmaceuticals[@b132-ceor-3-117]Specific needs of certain groups of people[@b132-ceor-3-117]Research and development[@b132-ceor-3-117]Price in other European Union countries[@b132-ceor-3-117]Market forecast[@b132-ceor-3-117]
  Sweden            Dental and Pharmaceutical Benefits Board Expert Board (decisions)[@b15-ceor-3-117],[@b109-ceor-3-117],[@b110-ceor-3-117]                                                              Yes[@b21-ceor-3-117]                       Yes[@b109-ceor-3-117]                                                   Not specified                                                                                                            Yes[@b21-ceor-3-117]                                           Yes (across patient subgroups)[@b15-ceor-3-117],[@b21-ceor-3-117]   Not specified                            Not specified                            Yes[@b21-ceor-3-117]                                                No[@b21-ceor-3-117]                                                                   Not specified                              Equity[@b35-ceor-3-117]"Reasonableness of cost from medical, humanitarian, and socio-economic perspective"[@b33-ceor-3-117]Solidarity[@b21-ceor-3-117]
  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117],[@b114-ceor-3-117]                                                       Not specified                              Not specified                                                           Not specified                                                                                                            Not specified                                                  Yes[@b108-ceor-3-117]                                               Not specified                            Not specified                            Yes ("value for money")[@b109-ceor-3-117]                           Not specified                                                                         Yes[@b108-ceor-3-117]                      Research and development[@b109-ceor-3-117]
  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Dutch Healthcare Insurance Board Committee of the Dutch Healthcare Insurance Board (recommendations)[@b31-ceor-3-117]                Yes[@b35-ceor-3-117]                       Yes[@b21-ceor-3-117]                                                    Not specified                                                                                                            Yes[@b35-ceor-3-117]                                           Yes[@b35-ceor-3-117],[@b117-ceor-3-117]                             Yes[@b35-ceor-3-117]                     Yes[@b35-ceor-3-117]                     Yes[@b35-ceor-3-117],[@b117-ceor-3-117]                             Yes[^¥^](#tfn6-ceor-3-117){ref-type="table-fn"}[@b21-ceor-3-117],[@b201-ceor-3-117]   Yes[@b35-ceor-3-117]                       RarityFeasibility of implementation[@b117-ceor-3-117]AccessibilityLevel of uncertainty in supporting evidence[@b115-ceor-3-117]Individual versus collective responsibility[@b201-ceor-3-117]Public health impact[@b35-ceor-3-117]
  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                    Yes[@b202-ceor-3-117]                      Yes[@b202-ceor-3-117]                                                   Yes[@b202-ceor-3-117]                                                                                                    Yes[@b202-ceor-3-117]                                          Yes (across patient subgroups)[@b202-ceor-3-117]                    Not specified                            Not specified                            Yes[@b202-ceor-3-117]                                               Not specified                                                                         Yes[@b35-ceor-3-117],[@b197-ceor-3-117]    Level of uncertainty in supporting evidence[@b196-ceor-3-117]Whether technology represents life-extending, end of life treatment[@b37-ceor-3-117]Wider societal costs and benefits[@b196-ceor-3-117]Public health impact[@b35-ceor-3-117],[@b197-ceor-3-117]Alignment with broad government priorities[@b202-ceor-3-117]ICERs of already funded programmes[@b13-ceor-3-117],[@b157-ceor-3-117]
  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b120-ceor-3-117]                                                             Yes[@b28-ceor-3-117]                       Not specified                                                           Not specified                                                                                                            Not specified                                                  Yes (across patient subgroups)[@b28-ceor-3-117]                     Not specified                            Not specified                            Yes[@b28-ceor-3-117]                                                Yes[@b174-ceor-3-117]                                                                 Yes[@b28-ceor-3-117]                       Level of uncertainty in supporting evidence[@b174-ceor-3-117]Wider societal costs and benefits[@b28-ceor-3-117]Alignment with broad government priorities[@b28-ceor-3-117]ICERs of funded programmes[@b28-ceor-3-117]

**Notes:**

In a well-defined population;

price proportionate to effect;

cost efficiency takes into account costs of treatment per patient, as well as costs of compensatory allowance due to lost income and costs of restoring patients' capacity to work;

efficiency of resource use within a single therapeutic area relative to existing interventions;

not a formal criterion.

###### 

Comparison of conditional reimbursement policy options for managing decision uncertainties

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                                                              **Policy options for addressing decision-making uncertainties**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                                                           YesAssociation of Austrian Social Security Institutions may remove pharmaceutical from benefit list in the wake of new clinical or economic evidenceManufacturer may suggest delisting pharmaceutical[@b21-ceor-3-117]                                                                                                                                                                   No[@b56-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Belgium           Minister of Social Affairs (decisions)Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117]                                                                                                                          Yes -- automatic reassessment of pharmaceuticals offering added therapeutic value 1.5 to 3 years after inclusion on benefit listMinister of Social Affairs or manufacturer may suggest delisting a pharmaceutical[@b41-ceor-3-117],[@b49-ceor-3-117]                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Financially or clinically based: For pharmaceuticals offering added therapeutic value for which the Drug Reimbursement Committee formulated a negative reimbursement recommendation[@b49-ceor-3-117]Financially based: Price-volume agreements -- "Provision Fund" established -- Advances paid by manufacturers are used to cover 75% of overrun[@b41-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                    Creation of Special Solidarity Fund -- Grants, on an individual basis, reimbursement of pharmaceuticals for rare diseases or rare indications unavailable in Belgium-- Only granted if patient meets certain criteria and has exhausted all other treatment options-- Must be prescribed by relevant specialist-- Reimbursement decisions made by College of Medical Doctors Directors[@b62-ceor-3-117]

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117]                                                                                                                                                                 Yes -- for "highly innovative" pharmaceuticals without evidence of effectiveness and "efficiency"Granted provisional reimbursement for 1 year, after which pharmaceutical is reassessed[@b65-ceor-3-117]                                                                                                                                                                                 Manufacturer may request a surcharge of up to 30% over the basic reimbursement level if evidence suggests pharmaceutical demonstrates "superior" therapeutic benefits[@b66-ceor-3-117]                                                                                                                                                                                                                                                                                             No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                                                        Pharmaceuticals reassessed as part of therapeutic class reviews every 5 yearsPharmaceutical may be scheduled for a separate reassessment when initial reimbursement decision is made if Reimbursement Committee considers it necessary to collect additional information about the use of the pharmaceutical in clinical practice before making a definitive decision[@b50-ceor-3-117]   No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Clinically based: Example: "No cure no pay" scheme for valsartan for high blood pressureIndividual level schemes-- Patient may apply for reimbursement on an individual basis, which requires evidence of treatment effect for continued reimbursement[@b46-ceor-3-117]-- Typically for patients who have exhausted all other options-- Period of reimbursement varies[@b68-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                               No information found

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                                                           No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Financially based: For all new pharmaceuticals -- price-volume agreements mandatory for 1 year following reimbursement decision[@b41-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      No information found

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]                                                   Yes -- for all pharmaceuticalsAutomatic reassessment every 3 to 5 years after inclusion on benefit list[@b182-ceor-3-117],[@b203-ceor-3-117]                                                                                                                                                                                                                                             No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                                                                 For pharmaceuticals Yes -- for all pharmaceuticalsAutomatic reassessment every 5 years after inclusion on benefit list[@b20-ceor-3-117]For medical devices Yes -- for devicesAutomatic reassessment within 5 years of inclusion on benefit list[@b20-ceor-3-117],[@b162-ceor-3-117]                                                                                                      No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               May provide provisional coverage for a set period during which "real-world" effectiveness and/or economic implications must be assessed through a study: -- To be carried out: By skilled teams in a limited number of selected centersUnder well-defined conditions of useUsing a protocol approved by French National Authority for Health Transparency CommitteeApplies to pharmaceuticals that: Target a large population;May be prescribed outside their labeled indications; orMay have a significant impact on health care organizations[@b16-ceor-3-117],[@b20-ceor-3-117]Also applies to medical devices -- French National Authority for Health specifies study protocol^l[@b20-ceor-3-117]^   For pharmaceuticals\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  For pharmaceuticals for serious or rare diseases May be granted temporary access in a hospital setting for 1 year[@b162-ceor-3-117]For "innovative" medical devicesMay establish "innovation point of contact" and an internal multidisciplinary network[@b162-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Financially based: Price-volume agreements -- Manufacturer must "pay back" the cost of sales exceeding those forecasted for the first 4 years [@b23-ceor-3-117],[@b43-ceor-3-117]-- Pharmaceuticals exempt from such schemes for various periods depending on their "improvement in medical benefit" (ie, improvement in medical benefit) level: "improvement in medical benefit" I -- 36 months; "improvement in medical benefit" II -- 24 months; "improvement in medical benefit" III -- 24 months at 50%; and "improvement in medical benefit" IV -- 24 months at 25%-- Also applies to "orphan drugs" (eg, eculizumab for paroxysmal nocturnal hemoglobinuria and galsulfase for mucopolysaccharidosis type VI)[@b41-ceor-3-117]                                                                                 

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                For medical devices and procedures May provide provisional coverage for a set period during which "real-world" effectiveness and/or economic implications must be assessed through a study[@b204-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             For pharmaceuticals\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No reimbursement limit for potentially effective technologies used to manage life-threatening technologies for which there are no alternatives[@b82-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Financially based: Price-volume agreements -- "target agreements": if prescription volume target is exceeded by 25%, manufacturers must "pay back" sickness funds (eg, insulin analogs, olanzapine, risperidone, clopidogrel, zolendronate, mycophenolic acid, everolimus, and cyclosporine)[@b41-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117]                                                                                                                         No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Hungary           Ministers of Health and FinanceNational Health Insurance Fund Administration (recommendations)[@b88-ceor-3-117],[@b89-ceor-3-117]                                                                                             No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Financially based: Price-volume agreements -- 12% of reimbursed sales must be paid to the Ministry by the manufacturer-- If Ministry spending on pharmaceutical exceeds agreed-to budget, the manufacturer must refund the Ministry an additional amount based on a predefined formula[@b41-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found

  Ireland           Products Committee of Corporate Pharmaceuticals Unit of Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117]                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]                                           No automatic/routine reassessment, with the exception of pharmaceuticals reimbursed under condition that additional studies would be conducted[@b25-ceor-3-117]                                                                                                                                                                                                                          No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               For pharmaceuticals classified as "potentially innovative" May require manufacturer to conduct additional studies within 3 yearsPharmaceuticals for patients enrolled in the studies must be covered by the manufacturer[@b25-ceor-3-117]Have established ongoing registries to monitor prescribing and assess "therapeutic value" in practice (real-world settings) in order to inform future management and reimbursed pricing decisions (eg, cetuximab, lenalidomide, ibritumomab, tiuxetan, palifermin, temporfin, and trastuzumab)[@b41-ceor-3-117]                                                                                                                                                 Clinically based: Pharmaceutical initially reimbursed by National Health Service at 50% or 100% for a fixed number of treatment cycles, after which it is only reimbursed for patients achieving predefined clinical response; manufacturer may be required to refund the cost of pharmaceutical in non-responding patients (eg, sunitinib, sorafenib, dasatinib, and nilotinib)Registries used to track outcomes included in scheme[@b47-ceor-3-117]Manufacturer initially provides pharmaceutical at no cost for a fixed period, after which National Health Service pays for pharmaceutical in patients achieving predefined clinical response (eg, donepezil)[@b41-ceor-3-117]Financially based: Expenditure cap -- Cost per patient per year cannot exceed a certain amount (eg, bevacizumab)[@b41-ceor-3-117]   Individual reimbursement -- Patients may be granted individual reimbursement of pharmaceuticals not on the benefit list if: No alternative existsRequested pharmaceutical is available in other European Union statesClinical trials are underwayPharmaceutical is already reimbursed for a different indication[@b96-ceor-3-117],[@b205-ceor-3-117]Establishment of "innovative medicines fund" -- Commits 20% of available resources to reimbursement of "innovative" pharmaceuticals, ranked from most to least innovative using the following criteria: Treats serious conditions that are lifethreatening or cause hospitalization or permanent disabilityUsed for risk factors for serious conditionsUsed for nonserious conditions[@b25-ceor-3-117],[@b188-ceor-3-117]-- If fund is overspent, manufacturers participate in refunding the system proportional to market share[@b95-ceor-3-117]

  Norway            Norwegian Medicines Agency (recommendations/decisions)[@b34-ceor-3-117],[@b98-ceor-3-117]Ministry of Health and Care Services (recommendations/decisions)Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]   Pharmaceuticals may be reassessed as part of ongoing therapeutic class reviews[@b34-ceor-3-117]                                                                                                                                                                                                                                                                                          No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Individual reimbursement -- For patients who have exhausted all reimbursed alternatives and/or have serious or rare conditions-- May be requested by specialists only-- Reimbursement decision made by Norwegian Labour and Welfare Organization-- Pharmaceutical does not need to have obtained market approval[@b34-ceor-3-117]

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117]Drug Management Team (recommendations)[@b99-ceor-3-117]                                                                                                                        No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b44-ceor-3-117],[@b101-ceor-3-117]                                                                                                                                  No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Financially based: Price-volume agreements -- Growth rate in pharmaceutical expenditures fixed per year; if exceeded, manufacturers must refund the system up to 69.6% of the coverage up to a predetermined amount, eg, €35 million (2006)[@b44-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No information found

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                                                                  Yes -- for all pharmaceuticalsAutomatic reassessment, but review period varies with the pharmaceutical; depends upon when additional evidence is expected to be available[@b128-ceor-3-117]                                                                                                                                                                                              No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117],[@b106-ceor-3-117]                                                                                           No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                                                                  No information found                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Sweden            Dental and Pharmaceutical Benefits Board Expert Board (decisions)[@b15-ceor-3-117],[@b206-ceor-3-117]--[@b209-ceor-3-117]                                                                                                     Yes -- for all pharmaceuticalsAutomatic reassessment, but review period varies with the pharmaceutical; depends upon when additional evidence is expected to be available[@b51-ceor-3-117],[@b135-ceor-3-117]Pharmaceuticals may also be reassessed as part of ongoing therapeutic class reviews[@b51-ceor-3-117],[@b135-ceor-3-117]                                                     Reimbursement price may be adjusted to reflect actual costs and benefits once such information becomes available (eg, continuous intraduodenal infusion of levodopa/carbidopa for advanced Parkinson's disease)[@b209-ceor-3-117]                                                                                                                                                                                                                                                  May require submission of evidence from studies collecting "real-world" data on clinical, economic, and quality of life outcomes[@b205-ceor-3-117],[@b209-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117],[@b114-ceor-3-117]                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                     "Innovation premium" -- Granted to innovative pharmaceuticals (ie, therapeutic breakthrough products)-- Surcharge of ≤20% of external reference price is added for a maximum of 15 years[@b113-ceor-3-117],[@b114-ceor-3-117],[@b205-ceor-3-117]                                                                                                                                                                                                                                   No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Dutch Healthcare Insurance Board Committee of the Dutch Healthcare Insurance Board (recommendations)[@b31-ceor-3-117]                                                        Yes -- for all pharmaceuticalsAutomatic reassessment -- time period not specified[@b31-ceor-3-117],[@b210-ceor-3-117],[@b211-ceor-3-117]                                                                                                                                                                                                                                                 No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               New inpatient pharmaceuticals with projected costs \>5% of hospital budget Granted provisional reimbursement for 3 years, during which studies collecting "real-world" data on cost-effectiveness must be conducted[@b119-ceor-3-117]High-cost pharmaceuticals for rare conditionsGranted provisional reimbursement for use in an academic hospital for 4 years, during which manufacturer must sponsor studies collecting "real-world" data on cost effectiveness and budget impact[@b119-ceor-3-117]                                                                                                                                                                                                   No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                                                            Yes -- for all technologiesAutomatic reassessment, but review period varies with the pharmaceutical; depends upon when additional evidence is expected to be available[@b13-ceor-3-117],[@b29-ceor-3-117],[@b157-ceor-3-117]                                                                                                                                                             Proposed "flexible pricing" scheme: -- Manufacturers can adjust the price of a pharmaceutical in response to emerging additional evidence on actual benefit or approval of a new indication which alters the value that the pharmaceutical offers to patients-- National Institute for Health and Clinical Excellence assesses whether new price and evidence represents "value for money" and may veto a new price on an existing indication[@b45-ceor-3-117],[@b48-ceor-3-117]   "Innovation pass" -- Selected "innovative" technologies are made available for 3 years, during which studies to collect data needed to inform standard National Institute for Health and Clinical Excellence processes are conducted[@b48-ceor-3-117]                                                                                                                                                                                                                                                                                                                                                                                                                                                    For pharmaceuticals "Patient access schemes"[@b42-ceor-3-117]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        End-of-life medicines guidance -- Pharmaceuticals used to extend life by at least 3 months for patients with less than 24 months to live may be reimbursed, even if ICER exceeds threshold range[@b37-ceor-3-117]--[@b48-ceor-3-117]Pharmaceuticals for rare conditions guidance -- May be reimbursed when ICER exceeds threshold range if:-- Target conditions in which incidence \<7000 patients/year in the UK-- There is sufficient evidence demonstrating that pharmaceutical offers substantial average increase in life expectancy over alternatives[@b205-ceor-3-117]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Financially based: Manufacturer proposes discounts or rebates to reduce the cost of a pharmaceutical to the National Health Service, thus improving its cost-effectiveness -- Manufacturer must obtain approval for such a scheme from the Department of Health prior to National Institute for Health and Clinical Excellence review[@b29-ceor-3-117],[@b212-ceor-3-117]--[@b214-ceor-3-117]Expenditure cap -- Cost per patient per year cannot exceed a certain amount (eg, ustekinumab and erlotinib)[@b45-ceor-3-117]\                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Clinically based: Manufacturer covers the cost of initial fixed number of cycle(s) of treatment, after which National Health Service pays for patients achieving predefined clinical response (eg, sunitinib)[@b45-ceor-3-117]National Health Service covers the cost of initial fixed number of cycles of treatment, after which manufacturer refunds the cost of treatment in patients failing to achieve predefined clinical response (eg, bortezomib)[@b40-ceor-3-117]National Health Service covers the cost of the pharmaceutical for a fixed period, after which the price is reduced or refunds are issued to achieve predefined ICER (eg, interferon β, glatiramer acetate, and azathioprine)[@b45-ceor-3-117]                                                                                               

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group New Medicines Group (recommendations)[@b120-ceor-3-117]                                                                                 Yes -- for all pharmaceuticalsAutomatic reassessment, but review period varies with the pharmaceutical; depends upon when additional evidence is expected to be available[@b174-ceor-3-117]                                                                                                                                                                                              No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                               No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No information found                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No information found
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of the role of manufacturers in centralized reimbursement processes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country**       **Centralized reimbursement review/decision-making body (role)**                                                                                                                      **Refer technology topics for reimbursement consideration**   **Participate in defining scope and/or protocol of assessment**   **Comment on draft protocol**          **Participate in consultations during assessment**   **Submit information to group preparing assessment report**   **Submit information to group preparing evaluation report**   **Present views during committee meetings**   **Nominate clinical and/or patient experts to make oral presentation to committee**   **Attend committee meeting**   **Comment on report and/or draft recommendations**   **Appeal recommendations or decisions**
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------- ---------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------ ---------------------------------------------------- -----------------------------------------
  Austria           Association of Austrian Social Security Institutions (decisions)[@b55-ceor-3-117]Pharmaceutical Evaluation Board (recommendations)[@b56-ceor-3-117]                                   Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No                                                            No                                            No                                                                                    No                             No                                                   Yes

  Belgium           Minister of Social Affairs (decisions)Drug Reimbursement Committee (recommendations)[@b9-ceor-3-117],[@b60-ceor-3-117]                                                                Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No                                                            No                                            No                                                                                    No                             Yes                                                  Yes

  Czech Republic    State Institute for Drug Control (decisions)[@b65-ceor-3-117],[@b176-ceor-3-117]                                                                                                      Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No information found                                          No information found                          No information found                                                                  No information found           No information found                                 Yes

  Denmark           Danish Medicines Agency (decisions)[@b68-ceor-3-117],[@b69-ceor-3-117],[@b121-ceor-3-117]Reimbursement Committee (recommendations)[@b68-ceor-3-117],[@b121-ceor-3-117]                Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No                                                            No                                            No                                                                                    No                             Yes, if recommendation is negative                   Yes

  Estonia           Ministry of Social Affairs (decisions)[@b72-ceor-3-117]Pharmaceuticals Committee (recommendations)[@b72-ceor-3-117]                                                                   Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No information found                                          No information found                          No information found                                                                  No information found           No information found                                 No information found

  Finland           Pharmaceuticals Pricing Board (decisions)[@b73-ceor-3-117],[@b74-ceor-3-117],[@b76-ceor-3-117]Pharmaceuticals Pricing Board Expert Group (recommendations)[@b75-ceor-3-117]           Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No                                                            No                                            No                                                                                    No                             Yes, if recommendation is negative                   Yes

  France            Ministry for Health and Social Security (decisions)[@b20-ceor-3-117],[@b78-ceor-3-117]French National Authority for Health (recommendations)[@b78-ceor-3-117]                         Yes                                                           Yes (multiple technology appraisals)\                             No                                     Yes (multiple technology appraisals)\                No (multiple technology appraisals)\                          No                                                            No                                            No                                                                                    No                             Yes                                                  Yes
                                                                                                                                                                                                                                                                        N/A (single technology appraisals)                                                                       N/A (single technology appraisals)                   N/A (single technology appraisals)                                                                                                                                                                                                                                                                                                                  

  Germany           Federal Joint Committee (decisions)[@b19-ceor-3-117]Institute for Quality and Efficiency in Health Care (recommendations)[@b19-ceor-3-117]                                            No                                                            Yes                                                               Yes                                    No                                                   Yes                                                           No                                                            No                                            No                                                                                    No                             Yes                                                  Yes (decisions only)

  Greece            Transparency Committee in the Reimbursement and Medicinal Products (makes decisions)[@b85-ceor-3-117]                                                                                 Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No information found                                          No information found                          No information found                                                                  No information found           No information found                                 No information found

  Hungary           Ministers of Health and FinanceNational Health Insurance Fund Administration (recommendations)[@b88-ceor-3-117]                                                                       Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No information found                                          No information found                          No information found                                                                  No information found           No information found                                 Yes

  Ireland           Health Service Executive (decisions)[@b91-ceor-3-117],[@b92-ceor-3-117],[@b147-ceor-3-117]                                                                                            Yes                                                           N/A                                                               N/A                                    N/A                                                  Yes                                                           No                                                            No                                            No                                                                                    No                             Yes                                                  Yes

  Italy             Italian Medicines Agency Technical Scientific Committee (decisions)[@b94-ceor-3-117]Italian Medicines Agency Pricing and Reimbursement Committee (recommendations)[@b95-ceor-3-117]   Yes                                                           N/A                                                               N/A                                    N/A                                                  No                                                            Yes                                                           No                                            No                                                                                    No                             Yes                                                  No

  Norway            Norwegian Medicines Agency (decisions)[@b98-ceor-3-117]Department of Pharmacoeconomics (recommendations)[@b98-ceor-3-117]                                                             Yes                                                           N/A                                                               N/A                                    N/A                                                  No information found                                          No information found                                          No information found                          No information found                                                                  No information found           No information found                                 Yes

  Poland            Ministry of Health (decisions)[@b99-ceor-3-117],[@b166-ceor-3-117]                                                                                                                    Yes                                                           N/A                                                               N/A                                    N/A                                                  No information found                                          No information found                                          No information found                          No information found                                                                  No information found           No information found                                 No information found

  Portugal          Ministry of Health (decisions)INFARMED (recommendations)[@b36-ceor-3-117],[@b44-ceor-3-117]                                                                                           Yes                                                           N/A                                                               N/A                                    N/A                                                  No information found                                          No information found                                          No information found                          No information found                                                                  No information found           No information found                                 Yes

  Scotland          National Health Service Scotland (decisions)[@b30-ceor-3-117]Scottish Medicines Consortium (recommendations)                                                                          Yes                                                           N/A                                                               N/A                                    N/A                                                  No                                                            Yes                                                           No                                            No                                                                                    No                             Yes                                                  Yes

  Slovakia          Ministry of Health (decisions)Reimbursement Committee for Medicinal Products (recommendations)[@b105-ceor-3-117]--[@b107-ceor-3-117]                                                  Yes                                                           N/A                                                               N/A                                    N/A                                                  No information found                                          No information found                                          No information found                          No information found                                                                  No information found           No information found                                 No

  Spain             Ministry of Health Directorate General of Pharmacy and Health Products; Inter-Ministerial Pricing Commission (decisions)[@b21-ceor-3-117],[@b108-ceor-3-117]                          No                                                            No                                                                No                                     Yes                                                  Yes                                                           No                                                            No                                            No                                                                                    No                             No                                                   No

  Sweden            Dental and Pharmaceutical Benefits Board Expert Board (decisions)[@b10-ceor-3-117],[@b104-ceor-3-117],[@b105-ceor-3-117]                                                              Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           Yes                                                           Yes                                           No                                                                                    No                             Yes                                                  Yes

  Switzerland       Swiss Federal Office of Public Health (decisions)Federal Drug Commission (recommendations)[@b113-ceor-3-117],[@b114-ceor-3-117]                                                       Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No information found                                          No information found                          No information found                                                                  No information found           No information found                                 Yes

  The Netherlands   Ministry of Health, Welfare and Sport (decisions)Dutch Healthcare Insurance Board Committee of the Dutch Healthcare Insurance Board (recommendations)[@b31-ceor-3-117]                Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           No                                                            No                                            No                                                                                    No                             No                                                   Yes

  United Kingdom    National Institute for Health and Clinical Excellence (decisions)Technology Appraisals Committee (recommendations)[@b7-ceor-3-117]                                                    Yes                                                           Yes (multiple technology appraisals)\                             No (multiple technology appraisals)\   No (multiple technology appraisals)\                 Yes (multiple technology appraisals)\                         Yes (single technology appraisals)\                           No                                            Yes                                                                                   No                             Yes                                                  Yes
                                                                                                                                                                                                                                                                        N/A (single technology appraisals)                                N/A (single technology appraisals)     N/A (single technology appraisals)                   N/A (single technology appraisals)                            N/A (single technology appraisals)                                                                                                                                                                                                                                                    

  Wales             Ministry for Health and Social Services (decisions)All Wales Medicines Strategy Group (recommendations)[@b120-ceor-3-117]                                                             Yes                                                           N/A                                                               N/A                                    N/A                                                  N/A                                                           Yes                                                           No                                            No                                                                                    Yes                            Yes                                                  Yes
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
